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ABSTRACT
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic pain disorder
characterized by at least six weeks of lower urinary tract symptoms and unpleasant
sensations (pain, pressure and discomfort) thought to be related to the urinary bladder and
not meeting exclusion criteria. While the etiology is not known, BPS/IC may involve a
“vicious circle” of uroepithelial dysfunction, inflammation and peripheral and central
sensitization. We propose that the urinary bladder inflammatory insult partly mediates
voiding dysfunction and visceral neurogenic pain characteristic of BPS/IC. Several
studies from our laboratory have already demonstrated the role(s) of cytokines and their
downstream targets in the functional alterations in micturition reflex pathways following
chemically (cyclophosphamide, CYP)-induced cystitis. More recently, the pleiotropic
protein, TGF-β, has been implicated in the pathogenesis of CYP-induced cystitis.
TGF-β is activated locally at the initial site of injury by protease-dependent or
protease-independent mechanisms to initiate a proinflammatory milieu. Depending on its
contextual cues, TGF-β may then aid in resolving the primary immune response and
support tissue repair. Though TGF-β is necessary to maintain normal immunological
function, its aberrant expression and activation may have detrimental effects on
responding tissues and cell types. A sustained increase in peripheral TGF-β reactivity,
such as what may be observed in chronic inflammatory bladder conditions, may influence
bladder afferent excitability to amplify nociceptive transmission and CNS input. The
subsequent sensitization of peripheral afferent nociceptors at the level of the DRG or
urothelium may promote spinal cord ‘wind-up’ and cascade into visceral hyperalgesia
and allodynia.
In the first aim of this dissertation we investigated the functional profile of TGF-β
isoforms and receptor (TβR) variants in the normal and inflamed (CYP-induced cystitis)
urinary bladder with qRT-PCR, ELISA, IHC and in vivo cystometry. Our studies
determined (i) the involvement of TGF-β in lower urinary tract neuroplasticity following
urinary bladder inflammation, (ii) a functional role for TGF-β signaling in the afferent
limb of the micturition reflex and (iii) urinary bladder TβR-1 as a viable target to reduce
voiding frequency with cystitis. In the second aim of this dissertation we investigated the
sensory components of the urinary bladder that may underlie the pathophysiology of
aberrant TGF-β activation with bladder-pelvic nerve electrophysiology and luciferinluciferase assays for ATP measurement. Our studies determined that TGF-β1 increased
bladder afferent nerve excitability by stimulating ATP release from the urothelium via
vesicular exocytosis mechanisms with minimal contribution from pannexin-1 channels.
Furthermore, blocking aberrant TGF-β signaling in CYP-induced cystitis with TβR-1
inhibition decreased afferent nerve excitability with an equivalent decrease in ATP
release.
Taken together, these results establish a causal link between an inflammatory
mediator, TGF-β, and intrinsic signaling mechanisms of the urothelium that may
contribute to the altered sensory processing of bladder filling to facilitate increased
voiding frequency. The distinct interactions of multiple mediators underscore the
challenges for single target therapies and support the development of combinatory
therapeutics for bladder dysfunction. Ultimately, these studies have increased our
understanding of functional disorders and visceral pain and have the potential to improve
the health of those suffering from inflammation-associated bladder syndromes.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1.1. Lower Urinary Tract
1.1.1. Anatomy
The lower urinary tract (LUT, bladder and urethra) is a division of the renal
system that functions to passively store kidney byproducts until it is appropriate to void.
To accomplish this, the urinary bladder is a muscular and membranous organ whose
structure embodies its reservoir function. Its external features are organized into an apex,
fundus, body and neck. The apex, or vertex, is on the anterior surface of the urinary
bladder and is associated with ligament remnants attaching to the umbilicus (Tank, 2009).
The posterior surface is the fundus and its most inferior aspect is termed the base of the
urinary bladder (Tank, 2009). The body typically represents the area between the apex
and the fundus and the bladder neck is the most caudal aspect of the inferior bladder
surface that is perforated by the internal urethral orifice (Tank, 2009).
The urinary bladder wall is divided into three layers: tunica mucosa, tunica
muscularis propria and tunica serosa/adventitia (Figure 1). The tunica mucosa consists of
transitional epithelium and a lamina propria (Figure 1). Transitional epithelial cells in the
urinary bladder are termed the urothelium and are arranged in basal, intermediate and
apical cell layers. Basal cells are monolayers directly attached to the basement membrane
(Lewis, 2000). Intermediate cells are generally larger in diameter than basal cells and
range from one to multiple cell layers depending on the species (Lewis, 2000). The
apical, or umbrella, cells are hexagonal in shape and range from 25-250 μm depending on
urinary bladder distention (L. A. Birder & K. E. Andersson, 2013; Lewis, 2000).
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Several distinct features of the luminal surface of umbrella cells establish
antiadherence and an impermeable barrier characteristic of the urinary bladder mucosa.
First, tight junction complexes comprised of occludin and claudin proteins regulate
paracellular transport between adjacent umbrella cells (L. A. Birder & K. E. Andersson,
2013). The apical membrane is also occupied by uroplakin, a crystalline plaque cell
surface protein that forms an asymmetric unit membrane to maintain impermeability
during bladder expansion (X. R. Wu, Kong, Pellicer, Kreibich, & Sun, 2009). Lastly, a
layer of proteoglycans on the mucosal surface of umbrella cells serves as an
antiadherence factor and provides yet another physical barrier between urinary
constituents and the lamina propria (Figure 1) (Janssen et al., 2013).
The extracellular matrix of the lamina propria is deep to the basement membrane
of the urothelium and contains a diverse array of interstitial cells, nerve terminals and
vasculature (Figure 1) (Andersson & McCloskey, 2013; L. A. Birder & K. E. Andersson,
2013). It has been suggested that the lamina propria may have an important role in
integrating epithelial and smooth muscle function due to its innervations and proximity to
the urothelium and tunica muscularis propria (Andersson & McCloskey, 2013). The
tunica muscularis propria consists of three smooth muscle layers termed the detrusor
(Figure 1). The internal and external layers are arranged longitudinally, whereas those in
the middle are circular (Andersson & Arner, 2004; Krstic, 2004). The smooth muscle
cells in the muscularis propria retain their classic spindle shape and are bundled together
by collagen-rich connective tissue (Andersson & Arner, 2004). External to the muscularis
propria, the tunica serosa surrounds the superior and lateral surfaces of the urinary
2

bladder wall, whereas, the retroperitoneal aspects contain a vascular, loose connective
tissue termed the tunica adventitia (Figure 1) (Krstic, 2004).
Caudal to the inferior surface of the urinary bladder is the urethra. Similar to the
urinary bladder wall, the urethral wall is composed of a tunica mucosa, tunica muscularis
propria and tunica adventitia. The tunica mucosa consists of transitional epithelium
proximal to the urinary bladder followed by nonkeratinized, stratified squamous
epithelium distally (Krstic, 2004; Yucel & Baskin, 2004). The tunica muscularis propria
is composed of inner and outer smooth muscle arranged longitudinally and circularly,
respectively (Krstic, 2004). In the male urethra, the circular smooth muscle fascicles join
with urinary bladder smooth muscle at the urethrovesical junction to form the internal
urethral sphincter (Krstic, 2004; Yucel & Baskin, 2004). The smooth muscle fascicles
along the proximal female urethra, however, do not appear to anatomically arrange into a
sphincter (Yucel & Baskin, 2004). Skeletal muscle of the urethral wall forms the external
urethral sphincter and extends along the membranous urethra in males to generate
voluntary pressure during bladder filling (Fowler, Griffiths, & de Groat, 2008). The
skeletal muscle fibers in the female urethra join to form an ‘external’ urethral sphincter
comprised of a sphincter urethrae, compressor urethrae and sphincter urethrovaginalis to
provide urinary continence through urethral and vaginal closure (Ashton-Miller &
DeLancey, 2007).
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Figure 1: Urinary bladder wall anatomy
Left: Stained human urinary bladder. Right: Tissues and cell types within the bladder wall. The mucosa
layer is comprised of the urothelium and the lamina propria that contains vasculature, lymphatics, nerves
and smooth muscle cells. The muscularis propria is comprised of detrusor smooth muscle cells and
surrounded by outer connective tissue layer termed the adventitia or serosa. Reprinted from BJU
International, 96(4), Neuhaus, J., Pfeiffer, F., Wolburg, H., Horn, L., Dorschner, W., Alterations in
connexin expression in the bladder of patients with urge symptoms, 670-676, Copyright (2005), with
permission from John Wiley and Sons. Reprinted from Physiological Review, 93(2), Birder, L., Andersson,
K.E., Urothelial signaling, 653-680, Copyright (2013), with permission from The American Physiological
Society.

1.1.2. Neural Control
The LUT is regulated by supraspinal, spinal and peripheral nervous system
(PNS) input to maintain “switch-like” patterns of storage and elimination activity and has
been previously reviewed in greater detail (Figure 2) (Fowler et al., 2008). Briefly,
bladder wall mechanoreceptors initiate visceral afferent (Aδ fibers) activity during the
storage phase that synapse on spinal interneurons (de Groat & Wickens, 2013; Fowler et
al., 2008). Spinal reflex pathways then facilitate storage by directly enhancing
thoracolumbar sympathetic outflow and somatomotor discharge or ascending, in some
species, to metencephalic integration centers (Figure 2) (de Groat & Wickens, 2013;
Fowler et al., 2008).
4

Spinal interneurons activate preganglionic sympathetic fibers from the
intermediolateral cell column of the lower thoracic (T10) through upper lumbar (L2)
spinal cord that form thoracic and lumbar splanchnic nerves (Beckel & Holstege, 2011;
Ochodnicky, Uvelius, Andersson, & Michel, 2013). The preganglionic fibers then
synapse on the prevertebral inferior mesenteric ganglia or paravertebral ganglia and
travel along the hypogastric and pelvic nerves, respectively (Fowler et al., 2008).
Sympathetic adrenergic neurotransmission on the urinary bladder smooth muscle βadrenergic receptors promotes bladder wall relaxation and accommodation (Ochodnicky
et al., 2013). Bladder filling is also facilitated by the activation of α-adrenergic receptors
on the internal urethral sphincter resulting in contraction of the urethral outlet
(Ochodnicky et al., 2013). Spinal reflex pathways not only enhance sympathetic outflow
but also α-motoneuron discharge from Onuf’s nucleus in the ventrolateral horn of the
sacral (S2-S4) spinal cord (Figure 2) (de Groat & Wickens, 2013). Propagation of this
signal along the pudendal nerve to the external urethral sphincter elicits skeletal muscle
contraction by activating nicotinic acetylcholine receptors to provide voluntary control
over urinary continence (Ochodnicky et al., 2013).
Upon reaching the tension threshold, bladder afferents (Aδ fibers) bypass local
spinal reflexes and ascend to the mesencephalic periaqueductal gray (PAG) (Figure 2).
Unlike the reflexes underlying the storage phase, the elimination phase relies on
supraspinal circuitry as evidenced by voiding dysfunction following lower thoracic spinal
cord injury (Beckel & Holstege, 2011; de Groat & Yoshimura, 2006). After cortical
processing, the PAG sends excitatory input to a region in the dorsolateral pontine
5

tegmentum termed the pontine micturition center (PMC) (Griffiths, 2002). The PMC then
sends descending cortical projections that synapse on preganglionic parasympathetic
neurons and inhibitory interneurons in the sacral spinal cord (Figure 2) (Beckel &
Holstege, 2011; Griffiths, 2002).
The preganglionic parasympathetic fibers arise from the intermediolateral cell
column of the human sacral (S2-S4) spinal cord to form pelvic nerves. Upon coursing
through and exiting the hypogastric and pelvic plexus, the fibers join the pelvic and
pudendal nerves to synapse on terminal ganglia and innervate the detrusor smooth muscle
and urethra (de Groat & Wickens, 2013; Ochodnicky et al., 2013). Cholinergic and nonadrenergic/non-cholinergic neurotransmission on the urinary bladder smooth muscle
promotes bladder wall contraction by activating muscarinic acetylcholine receptors and
purinergic receptors, respectively (Beckel & Holstege, 2011). Elimination of urine is also
facilitated by nitric oxide release onto the internal urethral sphincter resulting in a
relaxation of the urethral outlet (Beckel & Holstege, 2011). The PMC not only augments
parasympathetic outflow but also attenuates preganglionic sympathetic and αmotoneuron discharge to the LUT (Figure 2) (Griffiths, 2002). The descending cortical
projections terminating on inhibitory interneurons in the sacral spinal cord prevents
excitatory input into the urethral sphincters resulting in dilation of the urethral orifice and
continuous flow of urine. As distention of the urinary bladder decreases during the
elimination phase, ascending excitation to the dorsolateral metencephalon is diminished
and the storage phase is once again switched on.
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Figure 2: Neural control of continence and micturition
a: Storage reflex. Bladder wall mechanoreceptors initiate visceral afferent activity during the storage phase.
Spinal reflex pathways then facilitate storage by enhancing sympathetic discharge in the hypogastric nerve
and somatomotor discharge in the pudendal nerve. In some species, the pontine storage center may also
promote urethral contraction. Together, this has a net effect of contracting the urethra and relaxing the
detrusor smooth muscle to accommodate bladder filling. b: Micturition reflex. Upon reaching the tension
threshold, afferent nerve discharge in the pelvic nerve ascends to the pontine micturition center and/or the
periaqueductal gray (PAG). Descending cortical projections then activate parasympathetic discharge and
inhibit sympathetic and somatomotor discharge. This has a net effect of promoting bladder wall
contraction, relaxing the urethra and facilitating the elimination of urine. Reprinted by permission from
Macmillan Publishers Ltd: Nature Reviews Neuroscience, Fowler C.J., Griffiths D., de Groat W.C.. The
neural control of micturition. 9(6):453-466, copyright (2008).

1.1.3. Symptoms and Dysfunction
The terminology used in the following section is consistent with the
standardization report of LUT symptoms and function by the International Continence
Society and will refer to their definitions when appropriate (Abrams et al., 2002). Similar
to other clinical indications, LUT symptoms are the patient’s qualitative representation of
a purported condition. These symptoms, in particular, refer to a spectrum of LUT
functions that include storage, elimination and post micturition disturbances.
7

Symptoms associated with the storage phase include, but are not limited to,
“increased frequency, urgency and incontinence” (Abrams et al., 2002). The complaint
of increased urinary frequency is prevalent among both men and women with LUT
dysfunction and has been suggested to affect an individual’s quality of life as
demonstrated by a strong correlation between frequency and bothersome endorsements
(Coyne et al., 2009). Increased urgency is a complaint of the “sudden compelling desire
to pass urine” that may be accompanied by pain, pressure or discomfort associated with
the LUT (Abrams et al., 2002). Lastly, urinary incontinence includes a complaint of the
“involuntary leakage of urine” and may manifest in various forms and severities (Abrams
et al., 2002). It is important to note that incontinence is not representative of one
particular LUT dysfunction but rather can arise from multiple sources including stress,
comorbid disorders and congenital abnormalities (Cameron, Heidelbaugh, & Jimbo,
2013).
Symptoms associated with the elimination phase include “hesitancy, slow or
intermittent stream, straining and terminal dribble” (Abrams et al., 2002). These
symptoms generally involve complaints of the initiation and continuation of voiding and
alterations to their urine stream and appear to be more prevalent in men compared to
women (Abrams et al., 2002; Coyne et al., 2009). Symptoms associated with the post
micturition phase occur after voiding and include “incomplete emptying and post
micturition dribble” (Abrams et al., 2002). Although equally bothersome, post micturition
dribble may be more prevalent in men, whereas in women, incomplete emptying may be
more prevalent (Coyne et al., 2009). As briefly mentioned above, LUT symptoms are not
8

confined to urodynamic disturbances, but may also include unpleasant sensations of pain
or discomfort during storage or elimination. These sensations are generally perceived to
emanate from the urogenital organs and may exacerbate storage and elimination
symptoms (Le & Schaeffer, 2009).
1.2. Bladder Pain Syndrome/Interstitial Cystitis
1.2.1. Background
LUT signs and symptoms resembling what is currently termed bladder pain
syndrome (BPS)/interstitial cystitis (IC) have been documented throughout history and its
perspective has been previously reviewed in detail (Hanno, 2011). Briefly, Drs. Philip
Syng Physick and Joseph Parish first recognized an inflammatory condition called tic
doloureux of the bladder whose symptoms included chronic urinary frequency, urgency
and pelvic pain (J. K. Parsons & Parsons, 2004). Skene (Skene, 1887) expanded the
cystoscopic features of this concept in the late 19th century and introduced the term IC
which included ulceration of the mucous membrane and inflammation within the bladder
wall. Focal, ulcerative bleeding in the urinary bladder wall remained a hallmark of IC
due, in part, to the work of Hunner (Hunner, 1915) in the early 20th century (Hanno,
2011). Many patients, however, were misdiagnosed as current estimates suggest only 57% of those with BPS/IC present with bladder ulcerations (Hanno, 2011; Jones &
Nyberg, 1997).
In the absence of a formal classification for IC, the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) attempted to standardize its research
definition in 1987 by establishing a diagnostic criteria (Hanno, Staskin, Krane, & Wein,
9

1990). The criteria included the presence of “glomerulations on cystoscopic examination
or a classic Hunner ulcer, pain associated with the bladder, urinary urgency” and eighteen
exclusion conditions (Hanno, 2011; Hanno et al., 1990). After several iterations and
international consultations, the term IC was expanded to include BPS (Hanno et al., 2011;
van de Merwe et al., 2008). The patient selection for BPS is based on “chronic pelvic
pain, pressure or discomfort perceived to be related to the urinary bladder accompanied
by at least one other urinary symptom such as persistent urge to void or frequency”,
whereas, IC is “reserved for cystoscopic and histological features” (Abrams et al., 2002;
van de Merwe et al., 2008). At this time, the terms BPS and BPS/IC are analogous and is
defined by the American Urological Association Interstitial Cystitis Guidelines Panel as
at least six weeks of LUT symptoms and unpleasant sensations perceived to be related to
the urinary bladder and with no other clinically identifiable sources (Hanno et al., 2011).
1.2.2. Epidemiology
The epidemiology of BPS/IC is limited due to the absence of standardized
definitions, markers and examinations (Berry et al., 2011; Hanno, 2011; Jones & Nyberg,
1997; Sant & Hanno, 2001). Taking into account this variability, it is estimated that there
is a 5:1 female-to-male ratio among BPS/IC patients (Hanno, 2011; Jones & Nyberg,
1997). It is estimated that 300 per 100,000 women worldwide suffer from BPS/IC
(Hanno, 2011). In the United States alone, 3.3 to 7.9 million women are estimated to
meet the criteria for BPS/IC (Berry et al., 2011). As expected, BPS/IC puts an enormous
financial burden on the individual and economy as a whole. Health care costs for an
individual with BPS/IC ranges from 4 to 7 thousand dollars per year, while the economic
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burden approaches 500 million dollars per year in lost productivity and therapeutics
(Anger et al., 2011; Hanno, 2011).
1.2.3. Pathophysiology
While the primary insult underlying BPS/IC is not known, it has been suggested
that the pathophysiology is a “vicious circle” involving uroepithelial dysfunction,
inflammation, afferent nerve hyperexcitability and visceral hyperalgesia and allodynia
(Figure 3) (Sant, Kempuraj, Marchand, & Theoharides, 2007). This section will explore
said mechanisms that have been proposed to feed-forward to promote the chronicity of
LUT symptoms observed in BPS/IC (Sant et al., 2007).
The urothelium is a specialized, stratified epithelium that when intact provides a
non-adherent, passive barrier through tight junction proteins, plaque proteins and surface
proteoglycans (Lewis, 2000). Any perturbation to the components of this permeability
barrier may lead to increased infiltration into the bladder wall and exposure of the
interstitium to urinary constituents (Hurst et al., 1996; C. L. Parsons, 2011; C. L. Parsons,
Greene, Chung, Stanford, & Singh, 2005; C. L. Parsons & Hurst, 1990). The diffusion of
urinary constituents like potassium into the bladder interstitium may depolarize muscle
and nerve cells, inflame tissues, degranulate mast cells and cascade to the development of
LUT symptoms (Figure 3) (C. L. Parsons, 2011). Uroepithelial dysfunction specific to
BPS/IC, however, remains controversial. For example, Chelsky et al. (Chelsky et al.,
1994) demonstrated that the permeability in IC was comparable to the variation seen in
symptom-free controls, whereas, Parsons et al. (C. L. Parsons et al., 2005) demonstrated
abnormal permeability and potassium absorption in those with IC (Hanno, 2011). The
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abundance of studies for or against uroepithelial dysfunction in BPS/IC suggest it may
not be a primary insult but rather may occur in a subset of patients to exacerbate LUT
symptoms (Hanno, 2011).
In addition to the uroepithelial disruption, visceral inflammation also remains a
central pathological process in BPS/IC and has been suggested to underlie the
development of LUT symptoms (Figure 3). Inflammation within the urinary bladder
viscera is characterized by increased vasculature, mucosal irritation that may result in
barrier dysfunction and infiltration of inflammatory mediators (Erickson, Belchis, &
Dabbs, 1997; Grover, Srivastava, Lee, Tewari, & Te, 2011). The proliferation and
activation of mast cells, in particular, has received considerable attention in the urinary
bladder immune response (Sant et al., 2007). Mast cells secrete vasoactive chemicals to
promote innate and auto-immunity and their increased activity has been widely
demonstrated in BPS/IC (W. Boucher, el-Mansoury, Pang, Sant, & Theoharides, 1995;
Enerback, Fall, & Aldenborg, 1989; Kastrup, Hald, Larsen, & Nielsen, 1983;
Theoharides et al., 1995). The subsequent exposure in the bladder interstitium to
vasoactive chemicals, inflammatory mediators and neuropeptides from visceral
inflammation may lead to afferent nerve hyperexcitability and neurogenic inflammation
(Figure 3) (Vizzard, 2001; Yoshimura & de Groat, 1999; Y. Yu & de Groat, 2008).
The loss of inhibition on peripheral afferents (Aδ and C fibers) increases input
into the spinal cord and may eventually promote central sensitization (Sant et al., 2007).
An unregulated state of central and peripheral reactivity causes ‘wind-up’ which is
observed clinically as hyperalgesia and allodynia (Figure 3). In BPS/IC, hyperalgesia and
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allodynia are characterized by an elevated state of urinary bladder sensation that may
cause pain, pressure or discomfort and may result in increased urinary frequency and
urgency (Grover et al., 2011). The “vicious circle” continues as mast cell degranulation
and infiltration of mediators from uroepithelial dysfunction and/or visceral inflammation
sustain peripheral and central sensitization to establish visceral hyperalgesia/allodynia
and chronic LUT symptoms (Figure 3) (Sant et al., 2007).

Figure 3: Potential etiologic cascade and pathogenesis underlying BPS/IC
It is likely that BPS/IC has a multifactorial etiology that may act predominantly through one or more
pathways resulting in the typical symptom-complex. There is a lack of consensus regarding the etiology or
pathogenesis of BPS/IC but a number of proposals include a “leaky epithelium,” release of neuroactive
compounds at the level of the urinary bladder with mast cell activation, “awakening” of C-fiber bladder
afferents, and upregulation of inflammatory mediators including cytokines and chemotactic cytokines
(chemokines). Inflammatory mediators can affect CNS and PNS neural circuitry including central “windup” and nociceptor sensitization resulting in chronic bladder pain and voiding dysfunction. BPS/IC is
associated with diseases affecting other viscera and pelvic floors. Reprinted from Urology, 69(4 Suppl),
Sant, G.R., Kempuraj, D., Marchand, J.E., Theoharides, T.C., The mast cell in interstitial cystitis: Role in
pathophysiology and pathogenesis, S34-40, Copyright (2007), with permission from Elsevier. Reprinted
from BioMed Research International, 2014, Gonzalez, E.J., Arms, L., Vizzard, M.A., The role(s) of
cytokines/chemokines in urinary bladder inflammation and dysfunction, 1-17, Copyright (2014), with
permission from Hindawi Publishing Corporation.
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1.2.4. Animal Models
Numerous animal models have been implemented to determine the onset and
chronicity of LUT dysfunctions like BPS/IC. While one model cannot currently account
for the constellation of symptoms in BPS/IC, they each aid in identifying distinct
mechanisms underlying part of its pathophysiology. This section will explore a naturally
occurring cystitis model in felines and focus its review on experimental models of cystitis
induced chemically. It is important to note that models of BPS/IC are not limited to what
will be discussed in this section and exhaustive reviews have been previously published
(Bjorling, Wang, & Bushman, 2011; Fry et al., 2010; Westropp & Buffington, 2002).
The natural development of spontaneous LUT symptoms has been documented
in cats for several decades and is termed feline interstitial cystitis (FIC) (Bjorling et al.,
2011; Lyngset, 1972). Though the primary insult for FIC is not known, the
pathophysiology has marked similarities to BPS/IC including uroepithelial dysfunction
and visceral inflammation. Cats with FIC have been shown to have a disruption to the
epithelial cytoarchitecture that increased diffusion and infiltration of urinary constituents
(Gao, Buffington, & Au, 1994; Lavelle et al., 2000). Uroepithelial dysfunction in FIC
further leads to a peripheral upregulation of neuropeptides and inflammatory mediators
that alter bladder afferent soma size and increase input to the central nervous system
(CNS) (Birder et al., 2010). As previously discussed, the alterations to central and
peripheral reactivity following uroepithelial dysfunction and/or visceral inflammation
may promote the development of LUT symptoms that is observed in FIC and, by
extension, BPS/IC (Birder et al., 2010; Grover et al., 2011; Sant et al., 2007).
14

Despite these pathophysiological similarities, FIC as a model for BPS/IC is
limited due to its spontaneity and epidemiology. Investigators are practically and
financially restricted to structural and functional alterations following its spontaneous
induction and thus inadequately define insults preceding the development of FIC
(Westropp & Buffington, 2002). Furthermore, unlike BPS/IC, FIC occurs irrespective of
biological sex (Westropp & Buffington, 2002). While this may be due to a misdiagnosis
of BPS/IC in males, one cannot discount hormonal differences that may affect LUT
symptoms in humans (Robinson & Cardozo, 2003; Rohrmann et al., 2007).
LUT symptoms have also been induced by an assortment of chemical irritants
including, but not limited to: hydrochloric acid, acetic acid, protamine sulfate (PS) and
cyclophosphamide (CYP). The inflammation induced by intravesical instillation of
irritants like hydrochloric acid and acetic acid help reveal the anatomical, organizational
and functional alterations attributable to the visceral immune response (Bjorling et al.,
2011). Specifically, the functional and histological features following acid instillation are
similar to a BPS/IC subset and include urothelial hyperplasia, bladder ulceration, mucosal
edema, inflammatory cell infiltration and the development of LUT symptoms (Osorio,
Simckes, & Hellerstein, 1996; Yoshida, Kageyama, Fujino, Nozawa, & Yamada, 2010).
Though acid instillation allows for a more controlled environment than FIC, the studies
must be interpreted cautiously as the degree of inflammation resulting from exogenous
irritants may not be representative of the naturally occurring BPS/IC (Bjorling et al.,
2011).
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Unlike acid instillation, PS lacks a pervasive inflammatory element but rather
disrupts uroepithelial barrier function by targeting bladder surface proteoglycans (C. L.
Parsons, Stauffer, & Schmidt, 1988). Similar to the uroepithelial dysfunction observed in
FIC, PS instillation is sufficient to induce LUT symptoms (Soler et al., 2008). More
recently, PS has been used in conjunction with bacterial induced cystitis. Instillation of
both PS and E. coli lipopolysaccharide to respectively damage the urothelium and induce
a visceral inflammatory cascade may help clarify the interaction(s) of multiple processes
underlying LUT symptoms in BPS/IC (Bjorling et al., 2011; Stein, Pham, Ito, & Parsons,
1996).
CYP is an antineoplastic prodrug that requires enzymatic activation to release
phosphoramide mustard and the byproduct acrolein (Emadi, Jones, & Brodsky, 2009;
Powers & Sladek, 1983). A known adverse toxicity following systemic CYP
administration is hemorrhagic cystitis (Emadi et al., 2009). Hemorrhagic cystitis arises
from the bladder mucosal walls contact with acrolein, which increases vascular
permeability and results in bladder ulceration and hypertrophy (Batista et al., 2006). In
addition to hemorrhagic cystitis, systemic CYP treatment causes functional and
histological changes similar to BPS/IC including: mucosal edema, uroepithelial
dysfunction, inflammatory cell infiltration, afferent nerve hyperexcitability and the
development of LUT symptoms (M. Boucher et al., 2000; Eichel et al., 2001; Malley &
Vizzard, 2002; Stewart, 1986; Yoshimura & de Groat, 1999). CYP administration also
produces behavioral alterations consistent with the development of viscerosomatic pain
including decreased breathing rate, closing of the eyes and rounded back postures (M.
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Boucher et al., 2000). While the urinary bladder inflammatory response following
systemic CYP administration is greater than that observed in BPS/IC, this experimental
model of cystitis is appealing because of its route of administration (intraperitoneal) and
the chronicity and reproducibility of histopathological and functional alterations (Bjorling
et al., 2011).
1.3. Transforming Growth Factor-beta
1.3.1. Background
The transforming growth factor-beta (TGF-β) superfamily is comprised of at
least 35 pleiotropic proteins belonging to four subfamilies grouped by their sequence
homology—decapentaplegic-Vg-related (DVR), activin/inhibin, TGF-β sensu stricto and
other divergent members (Herpin, Lelong, & Favrel, 2004). Even though TGF-β
superfamily members have distinct expression patterns and regulate a variety of
functions, they are each translated as a pre-pro-protein that contains a peptide sequence
signaling to the endoplasmic reticulum, a N-terminal prodomain and a C-terminal mature
protein (Annes, Munger, & Rifkin, 2003; Herpin et al., 2004). After proteolytic
processing and posttranslational modifications, the C-terminal fragment is either secreted
as a mature protein dimer or forms a latent complex by maintaining a noncovalent bond
to the prodomain (Annes et al., 2003; Herpin et al., 2004).
The canonical members of TGF-β sensu stricto are one such proprotein to form
a latent complex. The interactions between the N-terminal prodomain, termed latency
associated peptide (LAP), and the mature TGF-β dimer is sufficient to sequester its
extracellular activity (Shi et al., 2011). Additionally, LAP associates with a latent TGF-β
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binding protein (LTBP) that regulates TGF-β bioavailability by chaperoning the complex
to the extracellular matrix (Todorovic et al., 2005). The subsequent activation of latent
TGF-β in the extracellular matrix via LAP cleavage occurs by protease-dependent or
protease-independent (protons, integrins, reactive oxygen species, etc.) mechanisms
(Annes et al., 2003; Barcellos-Hoff & Dix, 1996; Lyons, Keski-Oja, & Moses, 1988;
Murphy-Ullrich & Poczatek, 2000; van der Flier & Sonnenberg, 2001).
After its secretion, the mature or activated protein dimers transduce a signal
through transmembrane Ser-Thr receptor kinases (Herpin et al., 2004). The TGF-β family
of receptors is comprised of type I and type II receptors. Type II receptors selectively
bind their respective ligands to define part of the specificity of signal transduction
(Herpin et al., 2004). Ligand binding can either be “sequential” or “cooperative” and may
involve an accessory receptor (type III) to enhance ligand presentation (Massague, 1998).
Following receptor-ligand interaction, the type II receptor forms a heterotetrameric
complex with the type I receptor to transphosphorylate residues of the Gly-Ser (GS) box
(Massague, 1998). The activated type I receptors then phosphorylate Smad-dependent or
Smad-independent substrates to regulate the transcription of target genes (Derynck &
Zhang, 2003).
Smad proteins exist in three families: receptor-activated, common mediator and
inhibitory. Receptor-activated (R-) Smads dock onto type I receptors and are
phosphorylated on distal serine residues following receptor activation (Derynck & Zhang,
2003). Phosphorylated R-Smads dissociate from the receptor and interact with common
mediator Smad4 (Derynck & Zhang, 2003). The oligomeric R-Smad/Smad4 complex
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then translocates to the nucleus where it alters the transcription of target genes (Derynck
& Zhang, 2003). Type I receptors not only function through Smad signaling but may also
directly activate Smad-independent pathways such as TGF-β-activated kinase 1 (TAK1),
Ras, nuclear factor-κB (NF-κB) and the mitogen-activated protein kinase (MAPK)
subfamily members (Engel, McDonnell, Law, & Moses, 1999; Freudlsperger et al., 2013;
M. K. Lee et al., 2007; Moustakas & Heldin, 2005; Yamaguchi et al., 1995; L. Yu,
Hebert, & Zhang, 2002). The variety of direct and context-dependent downstream
signaling pathways preserves the multifunctional role(s) of TGF-β superfamily ligands
while providing the specificity required to control distinct target genes.
1.3.2. Immune Response
The canonical members of TGF-β sensu stricto maintain immunological
function by regulating the initiation and resolution of the immune response and a
comprehensive review has been previously published (M. O. Li, Wan, Sanjabi,
Robertson, & Flavell, 2006). Briefly, activated TGF-β at the site of injury may initiate a
proinflammatory milieu characterized by matrix remodeling and the recruitment and
activation of leukocytes (Ashcroft, 1999; M. O. Li et al., 2006). TGF-β may then aid in
resolving the primary immune response and support a milieu for tissue repair and
immunological memory to progress by suppressing the proliferation, differentiation and
survival of a subset of lymphocytes (M. O. Li et al., 2006).
To initiate an immune response, TGF-β may mobilize monocytes, mast cells and
granulocytes to the site of injury and influence their adhesion to the extracellular matrix
(Gruber, Marchese, & Kew, 1994; M. O. Li et al., 2006; Reibman et al., 1991; van Royen
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et al., 2002). While TGF-β may also recruit monocyte-derived macrophages, their
activation and function is typically inhibited to help resolve the immune response
(Ashcroft, 1999; S. Chen et al., 2005; Werner et al., 2000). Since immune cells continue
to infiltrate the site of injury, the extracellular matrix undergoes pathological remodeling
characterized by protease secretion and matrix degradation (Sorokin, 2010). TGF-β
supports the remediation and repair of these tissues by increasing the deposition of matrix
proteins and inhibiting protease activation (Leask & Abraham, 2004).
To sustain the resolution of the immune response, TGF-β may regulate T cell
proliferation, differentiation and survival (Gorelik & Flavell, 2002). TGF-β promotes T
cell growth arrest by suppressing interleukin 2 in areas of subthreshold antigen
presentation (Kehrl et al., 1986; M. O. Li et al., 2006). During the polarizing conditions
of the immune response, TGF-β maintains peripheral immunological tolerance by
inducing the transcription factor FoxP3 to promote CD4+CD25+ T cell differentiation to
regulatory T cells (M. O. Li et al., 2006; Marie, Letterio, Gavin, & Rudensky, 2005).
CD4+ T cell differentiation to the T helper (Th) 1 and Th2 cell lineages, however, is
inhibited by TGF-β mediated repression of the transcription factors T-bet and GATA-3,
respectively (Gorelik, Fields, & Flavell, 2000; Gorelik & Flavell, 2002). In addition to its
effects on CD4+ T cells, TGF-β may also attenuate the cytotoxicity of CD8+ T cells by
inhibiting its cytolytic genes (Thomas & Massague, 2005).
TGF-β not only stabilizes T cell expression and function to resolve the immune
response, but also regulates B cell proliferation, survival and development (Lebman &
Edmiston, 1999). TGF-β inhibits both the proliferation and cell cycle progression of B
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cells through Smad-dependent or Smad-independent pathways (Heldin, Landstrom, &
Moustakas, 2009; Kee, Rivera, & Murre, 2001; M. O. Li et al., 2006; Smeland et al.,
1987). TGF-β utilizes comparable B cell growth arrest pathways, as well as a distinct
Smad-independent pathway, to induce the apoptosis of B cells (M. O. Li et al., 2006;
Perlman, Schiemann, Brooks, Lodish, & Weinberg, 2001). Lastly, TGF-β may regulate
the maturation and activation of B cells through its induction of isotype switching,
suppression of B cell antigen receptor signaling and inhibition of immunoglobulin
secretion (Cazac & Roes, 2000; Kehrl, Thevenin, Rieckmann, & Fauci, 1991; M. O. Li et
al., 2006).
1.3.3. Nociception
The members of TGF-β sensu stricto contribute to both the peripheral and
central processing of noxious stimuli. TGF-β1 and TGF-β2 have been demonstrated to
increase de novo neuropeptide synthesis in the DRG that may directly sensitize primary
afferent nociceptors (Chalazonitis, Kalberg, Twardzik, Morrison, & Kessler, 1992;
Levine, Fields, & Basbaum, 1993). TGF-β may also influence DRG excitability by
regulating several ion channels including the voltage-gated potassium (Kv) channel and
TRPV-1. Application of recombinant TGF-β1 in vitro has been demonstrated to
downregulate KCNA4 gene expression and decrease A-type Kv currents in primary DRG
cultures (Zhu et al., 2012). Additionally, TGF-β1 Smad-independent signaling may
phosphorylate TRPV-1 on Thr residues and potentiate capsaicin-evoked calcium influx in
the DRG (Utreras et al., 2012; Utreras et al., 2013). The subsequent prolonged
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depolarization and an impaired repolarization may lead to an amplification of nociceptive
transmission and CNS input.
Unlike its role in the periphery, TGF-β in the CNS appears to be neuroprotective
by regulating neuronal and nonneuronal response to inflammatory injury (Lantero,
Tramullas, Diaz, & Hurle, 2012). Nonneuronal glial cells have recently been recognized
to enhance the proinflammatory milieu and facilitate the central processing of
nociception (O'Callaghan & Miller, 2010). Activated TGF-β in the CNS may inhibit the
proliferation and activation of these spinal glial cells to attenuate the induction of
neuropathic pain (Abutbul et al., 2012; Echeverry et al., 2009; Xiao, Bai, Zhang, & Link,
1997). TGF-β may further reduce excitatory synaptic transmission of second-order
neurons by directly suppressing the proinflammatory milieu in the spinal cord (Echeverry
et al., 2009). As a result of its biphasic and modulatory role in the peripheral and central
transmission of nociception, TGF-β appears to have a profound impact on the perception
of pain and may initiate, in part, pathological pain syndromes.
1.3.4. Role(s) in Cystitis
TGF-β ligands and its cognate receptors are expressed at low, basal levels in rat
urinary bladder tissues (Gonzalez, Girard, & Vizzard, 2013). Following chemically
(CYP)-induced cystitis of varying durations, TGF-β ligand and receptor expression
appears to display a time- and tissue-dependent regulation. TGF-β exhibits a delayed, but
sustained, increase in urinary bladder gene and protein expression 8-48 h after CYP
treatment (Gonzalez et al., 2013; Tyagi et al., 2009; Zhang & Qiao, 2012). Furthermore,
urinary excretion of active and latent TGF-β1 is increased up to 100-fold 24 h after acute
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CYP treatment (Tyagi et al., 2009). The aforementioned regulation of TGF-β gene and
protein expression has been suggested to be more pronounced in the afferent limb of the
micturition reflex suggesting a possible role in the development of LUT symptoms
(Gonzalez et al., 2013). Its role in micturition reflex dysfunction was confirmed with
cystitis and the pharmacological inhibition of aberrant TGF-β signaling. SB505124, a
potent inhibitor of TGF-β type I receptor kinase activity, decreased urinary frequency and
increased bladder capacity, void volume and intercontraction intervals 48 h following
CYP-induced cystitis (Gonzalez et al., 2013). These studies raise the possibility of
targeting TGF-β at the level of the urinary bladder to alleviate voiding dysfunction with
cystitis.
1.4. ATP and Purinergic Receptor/Signaling
1.4.1. Background
The urothelium releases neuroactive transmitters, in particular ATP, from its
apical and basolateral surfaces in response to physical and chemical stimuli (L. Birder &
K. E. Andersson, 2013; Burnstock, 2014). ATP and other nucleotides derived from the
urothelium can be released through several mechanisms that include transporters, ion
channels or vesicular exocytosis (Bodin & Burnstock, 2001; Wang et al., 2005).
Extracellular ATP that is not degraded by ectonucleotidases or exonucleotidases is then
able to stimulate autocrine or paracrine pathways that may aid in the sensory transduction
to the CNS (Schwiebert & Zsembery, 2003). The transduction pathways within the
urinary bladder are affected by receptor subtype expression and their proximity to the
urothelium. The tissues and cell types that may contribute to purinergic or pyrimidinergic
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signaling include the urothelium (Dunning-Davies, Fry, Mansour, & Ferguson, 2013; W.
Yu, Zacharia, Jackson, & Apodaca, 2006), ICC (Y. Li et al., 2013), smooth muscle cells
(Gopalakrishnan et al., 2002; Yang et al., 2000) and suburothelial nerve fibers (L. Birder
& K. E. Andersson, 2013; Gonzalez, Merrill, & Vizzard, 2014).
1.4.2. P2X and P2Y Receptor Expression and Function in the LUT
P2-purinoceptors are classified as ligand-gated ion channels, P2X, or G-protein
coupled receptors, P2Y (Fredholm et al., 1994). There are currently seven P2X subunits
(P2X1-7) that may arrange as heteromeric or homomeric ligand-gated ion channels and
eight metabotropic P2Y subunits (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13,
P2Y14) that may couple to Gs, Gi or Gq (Abbracchio et al., 2006; North, 2002). While
the kinetics and tissue distribution of each P2-purinoceptor differs, there is substantial
evidence that many of these subunits are functionally expressed throughout the urinary
bladder urothelium, lamina propria and detrusor smooth muscle.
The distribution of P2X and P2Y receptors in the urothelium has been described
in multiple species, including rodents, felines and humans. P2X2 and P2X4-7 receptor
immunoreactivity (IR) was detected in the rodent urothelium, whereas, positive IR was
detected for P2X1-7 in the feline urothelium (Table 1) (Birder et al., 2004; H. Y. Lee,
Bardini, & Burnstock, 2000; Vial & Evans, 2000). In the human bladder urothelium,
glycosylated P2X2 and P2X3 transcript and protein expression has also been detected
(Tempest et al., 2004). There appears to be less diversity in the uroepithelial distribution
of P2Y receptors where P2Y2 and P2Y4 transcript and protein expression has been
demonstrated in cultured rat uroepithelial cells (Chopra et al., 2008). Additionally, in the
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human uroepithelial cell line, UROtsa, P2Y1, P2Y2 and P2Y11 transcript expression was
detected (Save & Persson, 2010).
Nucleotides and their metabolites seem to have an intricate role in ATP release
and P2 receptor signaling in the urothelium. More specifically, adenosine diphosphate
(ADP) has been demonstrated to evoke ATP release from the urothelium, whereas
adenosine exerts inhibition on ATP release via A1 receptors (Dunning-Davies et al.,
2013; Mansfield & Hughes, 2014). The diverse expression of purine and pyrimidine
receptor subtypes in the urothelium also allows for distinct signal transduction (Chopra et
al., 2008; H. Y. Lee et al., 2000; Tempest et al., 2004). The activation of P2Y, but not
P2X, receptors on the urothelium evokes ATP release suggesting urothelial P2Y
receptors may contribute to purinergic neurotransmission (Chopra et al., 2008; G. Sui et
al., 2014).
The urinary bladder lamina propria is deep to the mucosal basement membrane
and includes loose connective tissue, vasculature, lymphatics, nerves and interstitial cells
(Andersson & McCloskey, 2013). A population of interstitial cells in the lamina propria
(ICC-LP) also express P2X3, P2Y2, P2Y4 and P2Y6 receptors and are proposed to form
a functional syncytium with smooth muscle cells (Table 1) (Drumm, Koh, Andersson, &
Ward, 2014; G. P. Sui, Wu, & Fry, 2006). In response to ATP, ICC-LP generate P2Ydependent intracellular calcium transients followed by inward currents (C. Wu, Sui, &
Fry, 2004). These ATP-generated transients may then propagate to smooth muscle cells
via gap junctions to alter contractility (Drumm et al., 2014). Although the mechanism
coupling ICC-LP to sensory activity is not yet known, the localization of ICC-LP and its
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responsiveness to ATP suggest they may have a regulatory role in the afferent limb of the
micturition reflex (C. Wu et al., 2004). In addition to the functional syncytium with ICCLP, urinary bladder smooth muscle cells express P2X1–P2X6 and P2Y receptors (Dutton,
Hansen, Balcar, Barden, & Bennett, 1999). P2X1 receptors have received much of the
focus on bladder contractility due to their contributions to nerve evoked bladder
contractions (Vial & Evans, 2000). More recently, P2Y6 receptors have also been
demonstrated to modulate bladder smooth muscle tone and augment P2X-mediated
bladder contraction (W. Yu, Sun, Robson, & Hill, 2013).
Afferent (and efferent) nerves terminating in the urothelium, lamina propria and
detrusor smooth muscle have received much of the attention in characterizing P2purinoceptor distribution (Table 1). While the transcript and protein expression of all
seven P2X subunits (P2X1-7) have been detected in the rodent DRG, there appears to be
a differential distribution of P2X2 and P2X3 depending on spinal cord level (X. Chen &
Gebhart, 2010; Ruan et al., 2005; Xiang, Bo, & Burnstock, 1998). P2X2 mRNA has been
detected in both thoracolumbar and lumbosacral urinary bladder afferent neurons, but
transcripts at the thoracolumbar level appear to be co-expressed with P2X3 (X. Chen &
Gebhart, 2010). P2X3 transcripts, on the other hand, appear to be restricted to small- and
medium-diameter afferent neurons and have a greater frequency of expression in
thoracolumbar than lumbosacral neurons (Bradbury, Burnstock, & McMahon, 1998; X.
Chen & Gebhart, 2010; Ruan et al., 2005). Similar to the urothelium, there appears to be
less diversity in the distribution of P2Y receptors in DRG neurons. P2Y1, P2Y2 and
P2Y4 transcript expression has been detected in rodent DRG neurons with P2Y1
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restricted to small-diameter neurons and P2Y4 to medium- and large-diameter neurons
(Ruan & Burnstock, 2003). P2Y2 and P2Y4, in particular, have been detected in
thoracolumbar and lumbosacral bladder afferent neurons by retrograde labeling (X. Chen,
Molliver, & Gebhart, 2010).
Although not yet conclusive, the proximity of afferent nerve terminals to the
urothelium indicates a role in purinergic sensory transduction. Previous studies have
established the functional contributions of P2X2 and P2X3 receptors to the afferent limb
of the micturition reflex (Kaan et al., 2010). P2X3 receptor-mediated mechanisms have
been demonstrated to contribute to both nociceptive and non-nociceptive
mechanosensory transduction in the bladder (Rong, Spyer, & Burnstock, 2002).
Furthermore, mice lacking P2X2/P2X3 receptor subunits exhibit decreased urinary
bladder reflexes and decreased pelvic afferent nerve activity in response to bladder
distention (Cockayne et al., 2005). The functional contributions to bladder sensory
neuron sensitization have also been demonstrated with P2Y2 receptors (X. Chen et al.,
2010). P2Y2 receptor activation was able to facilitate P2X2 and P2X3 evoked currents
and increase bladder neuron excitability (X. Chen et al., 2010).
Table 1: Purinergic receptors/channels in the LUT
Purinergic receptors are functionally distributed throughout the tissues and cell types of the urinary bladder.
Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate; BAN, bladder afferent nerve;
Det, detrusor; ICC, interstitial cell of Cajal; P, purinergic; UC, urothelial cell; UDP, uridine diphosphate;
UTP, uridine triphosphate. *Species differences. Reprinted by permission from Macmillan Publishers Ltd:
Nature Reviews Urology, Merrill, L., Gonzalez, E.J., Girard, B.M., Vizzard, M.A.. TRP channels and
purinergic signaling involvement in the urothelial sensory system in the urinary bladder. In press, copyright
(2016).
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Purinergic
Major
receptors/channels activator(s)
P2X (1-7)
ATP

P2Y (1, 2, 4 and 6)

P1

Nucleotides
(ATP; ADP;
UTP; UDP)
Adenosine

LUT distribution

LUT function

UC, Det, ICC, BAN* Visceral
mechanosensation,
BAN sensitivity
UC, Det, ICC, BAN* Visceral
mechanosensation,
BAN sensitivity
UC, Det, SubU*
Voiding threshold

1.4.3. Role(s) in Cystitis
Of the seven P2X subunits, P2X2 and P2X3 have been suggested to be involved
in the sensitization of urinary bladder sensory transduction with cystitis. Specifically,
P2X2 and P2X3 protein expression in the human bladder urothelium has been
demonstrated to increase in IC (Tempest et al., 2004). Likewise, P2X2 transcript
expression was increased in mouse thoracolumbar DRG neurons with cyclophosphamide
(CYP)-induced cystitis (X. Chen & Gebhart, 2010). Inhibition of P2X3 or P2X2/3
receptors with A-317491 following CYP-induced cystitis reduced non-voiding
contractions and residual urine volume and increased intermicturition intervals
suggesting a role for purinergic signaling in bladder hyperreflexia with cystitis (Ito,
Iwami, Katsura, & Ikeda, 2008).
CYP-induced cystitis has also been demonstrated to increase peak urinary
bladder afferent nerve activity that was significantly decreased following P2X receptor
antagonist (TNP-ATP or PPADS) instillation (Y. Yu & de Groat, 2008). The significance
of P2X3 specifically in bladder afferent nerve sensitization was demonstrated with P2X3null mice and its attenuation of P2X agonist (ATP or α,β-meATP) induced afferent nerve
excitation (Vlaskovska et al., 2001). Additionally, following CYP-induced cystitis,
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thoracolumbar rat DRG neurons increased homomeric P2X3 current, whereas,
lumbosacral rat DRG neurons increased heteromeric P2X2/3 current (Dang, Lamb,
Cohen, Bielefeldt, & Gebhart, 2008). While CYP-treated urinary bladder neurons exhibit
increased responsiveness to purinergic agonist application, the changes in P2X subtypes
do not appear to be conserved across species (X. Chen & Gebhart, 2010; Dang et al.,
2008). For instance, homomeric P2X2 currents not seen in rat DRG neurons increased in
mouse lumbosacral DRG neurons (X. Chen & Gebhart, 2010).
Although the role of P2Y receptors in urinary bladder sensory transduction is
still being resolved, P2Y2 has been implicated in bladder afferent hyperexcitability. UTP,
a P2Y2 and P2Y4 agonist, application depolarized the resting membrane potential and
increased action potential frequency in bladder afferent neurons (X. Chen et al., 2010).
UTP application also potentiated homomeric P2X2 current in wildtype (WT) but not
P2Y2-null mice suggesting P2Y2 may contribute to P2X-mediated afferent nerve
sensitization that was observed with cystitis (X. Chen et al., 2010).
1.4.4. Role(s) in Human Bladder Dysfunction
Increased levels of urinary ATP have been demonstrated in patients with IC
(Sun, Keay, De Deyne, & Chai, 2001), OAB (Silva-Ramos et al., 2013) and other
functional disorders of the urinary bladder (Burnstock, 2014). Primary bladder urothelial
cells taken from these patients also exhibit increased ATP release in response to
mechanical stretch (Sun et al., 2001), hypotonic stress (Sun & Chai, 2006) or electrical
field stimulation (Kumar, Chapple, Rosario, Tophill, & Chess-Williams, 2010). In
addition to increased urothelial-derived ATP release, changes in P2X receptor subtype
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expression within various bladder tissues have also been demonstrated in patients with IC
(Tempest et al., 2004), detrusor instability (O'Reilly et al., 2002) or bladder outlet
obstruction (O'Reilly et al., 2001). The established role(s) of purinergic signaling in
bladder sensation suggest that these neurochemical alterations may contribute to the
development of LUT symptoms in these patients. Thus, an alternative therapeutic
approach to improve bladder function may be to target purinergic neurotransmission
within sensory components of the micturition reflex (Burnstock, 2011).
1.5. Project Goals and Hypotheses
BPS/IC is a major unresolved health concern in the United States with an
economic burden approaching $500 million per year in lost productivity and health care.
BPS/IC is defined by at least six weeks of dysuric symptoms and unpleasant sensations
(visceral pain and discomfort) perceived to be related to the urinary bladder and in the
absence of other clinically identifiable sources. Despite advancements in our
understanding of the biological mechanisms of these pain syndromes, current
pharmaceutical and behavioral therapies are ineffective and fail to completely resolve
pathological symptoms. There is, therefore, a critical need to understand mechanistically
the neurochemical, functional and organizational alterations underlying BPS/IC and how
this translates into the constellation of clinical symptoms. In the absence of such
knowledge and effective management, BPS/IC continues to negatively impact the
economy and those suffering from BPS/IC continue to have physical and psychological
health dysfunction.
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Our long-term research goal is to develop successful therapeutic interventions in
the treatment of BPS/IC. The objective of this dissertation is to identify and characterize
a novel neurochemical alteration in the micturition reflex pathway and to determine its
functional role in modulating micturition reflexes. Our central hypothesis is that the
pleiotropic protein, TGF-β, and its cognate receptors contribute to afferent nerve
hyperexcitability that may facilitate increased voiding frequency in an experimental
cystitis model of BPS/IC. Identifying novel components of the urinary bladder
inflammatory response underlying dysfunction provides a basis for eventual preclinical
and clinical trials.
In Chapter 2 of this dissertation we explored the functional expression of TGF-β
ligands and receptors in the inflamed urinary bladder. We hypothesized that aberrant
expression will compartmentalize to distinct tissues to reflect the inflammatory state of
the urinary bladder and contribute to bladder dysfunction. In Chapter 3 of this dissertation
we explored the sensory components of the urinary bladder that may underlie the
pathophysiology of aberrant TGF-β activation. We hypothesized that TGF-β1 will
contribute to bladder afferent nerve excitability through enhanced ATP release from the
urothelium and purinoceptor activation. At the conclusion of these studies, we will have
characterized TGF-β ligand and receptor lower urinary tract expression and provided
evidence for a role of TGF-β signaling in bladder dysfunction. These studies will not only
increase our understanding of functional disorders and visceral pain, but also have the
potential to improve the health of those suffering from inflammation-associated bladder
syndromes.
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CHAPTER 2: EXPRESSION AND FUNCTION OF TRANSFORMING GROWTH
FACTOR-BETA ISOFORMS AND COGNATE RECEPTORS IN RAT URINARY
BLADDER FOLLOWING CYCLOPHOSPHAMIDE-INDUCED CYSTITIS
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Abstract
Numerous proinflammatory cytokines have been implicated in the reorganization of
lower urinary tract function following cyclophosphamide (CYP)-induced cystitis. The
present study investigated the functional profile of three pleiotropic transforming growth
factor-beta (TGF-β) isoforms and receptor (TβR) variants in the normal and inflamed
(CYP-induced cystitis) rat urinary bladder. Our findings indicate that TGF-β (1, 2 and 3)
and TβR (1, 2 and 3) transcript and protein expression were regulated to varying degrees
in the urothelium or detrusor smooth muscle following intermediate (48 h; 150 mg/kg,
i.p.) or chronic (75 mg/kg, i.p.; once every three days for ten days), but not acute (4 h;
150 mg/kg, i.p.), CYP-induced cystitis. Conscious, open outlet cystometry was
performed to determine whether aberrant TGF-β signaling contributes to urinary bladder
dysfunction following intermediate (48 h) CYP-induced cystitis. TβR-1 inhibition with
SB505124 (5 µM) significantly (p ≤ 0.001) decreased voiding frequency and increased
bladder capacity (2.5-fold), void volume (2.6-fold) and intercontraction intervals (2.5fold) in CYP-treated (48 h) rats. Taken together, these results provide evidence for: (i) the
involvement of TGF-β in lower urinary tract neuroplasticity following urinary bladder
inflammation, (ii) a functional role of TGF-β signaling in the afferent limb of the
micturition reflex and (iii) urinary bladder TβR-1 as a viable target to reduce voiding
frequency with cystitis.
Keywords: inflammation, transforming growth factor-β, urothelium, detrusor smooth
muscle, cyclophosphamide

58

Introduction
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is defined by the presence
of dysuric symptoms and unpleasant sensations (visceral pain and discomfort) perceived
to be related to the urinary bladder lasting longer than 6 weeks and in the absence of
other clinically identifiable sources (25). While the etiology remains unknown,
overlapping clinical signs and symptoms suggest an involvement of microbial infection
(14), submucosal immune cell infiltration (10), disrupted urothelial cell permeability (34)
or inflammation (44) (for review 22). We propose that micturition dysfunction and
visceral neurogenic pain associated with IC/BPS are partly mediated by the urinary
bladder inflammatory response (18, 21, 41). Several studies have already established the
role of proinflammatory cytokines and their downstream targets in the organizational (19,
31) and functional (3, 29) alterations in micturition reflex pathways following chemically
(cyclophosphamide; CYP)-induced cystitis. Most recently, the inflammatory mediator,
TGF-β, has been implicated in the pathogenesis of CYP-induced cystitis (45, 55).
The TGF-β superfamily is comprised of at least 35 structurally related
pleiotropic proteins (28). In addition to classical TGF-β, the superfamily can be
subdivided into bone morphogenetic proteins (BMPs), activins/inhibins, growth and
differentiation factors (GDFs), anti-müllerian hormone (AMH) and nodal (for review 30).
In mammals, the prototypic TGF-β cytokine exists in three isoforms (TGF-β1, TGF-β2
and TGF-β3) and is synthesized as a 75 kDa homodimeric propeptide, in which the
mature growth factor is non-covalently bound to a pro-domain (latency-associated
protein, LAP) (1). During secretion, covalent interactions between LAP and a
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glycoprotein, latent TGF-β Binding Protein (LTBP), translocate the latent complex to the
extracellular matrix where it can be activated through protease-dependent (54) or
protease-independent (thrombospondins, integrins, reactive oxygen species and protons
(6, 35, 38, 47)) mechanisms (for review 1). The destabilization of TGF-β/LAP and
LAP/LTBP releases an activated TGF-β dimer that forms a heterotetrameric receptor
complex comprised of transforming growth factor-β type I receptor (TβR-1) and TβR-2.
Ligand binding can also be enhanced through a third co-receptor (TβR-3) that lacks an
intracellular signaling domain (52). To propagate an intracellular signal, intrinsic
serine/threonine kinase activity of TβR-2 transphosphorylates TβR-1 to initiate receptor
regulated SMAD-dependent or SMAD-independent transduction pathways (33).
The maintenance and modulation of TGF-β signaling is essential for epithelial
cell cycle progression, proliferation and apoptosis (26), as well as immune cell function
and inflammation (7). The present study examined the transcriptional and translational
regulation of TGF-β (1, 2 and 3) and TβR (1, 2 and 3) in the rat urinary bladder
inflammatory response and the role for TGF-β signaling in urinary bladder dysfunction
following CYP-induced cystitis. Cytotoxicity in the urinary bladder accompanying CYP
metabolism increases urinary bladder permeability (16), urothelial hyperplasia and
voiding frequency (43), in addition to altering somatic sensitivity (23, 24), neurochemical
(48, 50) and electrophysiological (53) properties of micturition reflex function.
Therefore, CYP-induced cystitis permits a controlled, systematic identification of
inflammatory mediators underlying urinary bladder dysfunction that would otherwise be
inaccessible with a clinical population (18). With this in mind, we determined (i) the
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temporal and tissue (urothelium and detrusor smooth muscle) expression of TGF-β (1, 2
and 3) and TβR (1, 2 and 3) urinary bladder transcripts following CYP-induced cystitis
(acute, intermediate or chronic); (ii) the temporal expression of TGF-β (1, 2 and 3)
urinary bladder protein following CYP-induced cystitis; (iii) the temporal and tissue
(urothelium and detrusor smooth muscle) expression of TGF-β1 and TβR (1, 2 and 3)
using immunohistochemistry following CYP-induced cystitis and (iv) the functional
effects of pharmacological TβR-1 inhibition using conscious, open outlet cystometry
following intermediate (48 h) CYP-induced cystitis.
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Materials and Methods
Animals
Naïve adult female Wistar rats (200-375 grams) purchased from Charles River
Laboratories (Wilmington, MA) were housed two per cage and maintained in standard
laboratory conditions with food and water available ad libitum. Estrous cycles were not
determined at any point in these studies. Experimental procedures were approved by the
University of Vermont Institutional Animal Care and Use Committee (protocol 08-085)
and experimentation was in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals (8th edition).
Induction of CYP-induced cystitis
Female Wistar rats (n=4-8 per condition) received either no treatment, acute
(150 mg/kg), intermediate (150 mg/kg) or chronic (75 mg/kg) intraperitoneal (i.p.)
injections of cyclophosphamide (CYP; Sigma Aldrich, St. Louis, MO). Following CYP
(150 mg/kg, i.p.) treatment, rats were harvested either 4 (acute) or 48 (intermediate)
hours (h) post injection (5, 11, 31). For chronic CYP (75 mg/kg, i.p.) treatment, rats
received injections every third day for ten days and tissues were harvested on the tenth
day (5, 11, 31).
Antibodies
Polyclonal primary antibodies were purchased from Santa Cruz Biotechnology,
Inc. (Dallas, TX): rabbit anti-TGF-β1 (sc-146, 1:1000), rabbit anti-TβR-1 (sc-398,
1:5000), rabbit anti-TβR-2 (sc-220, 1:2000), goat anti-TβR-3 (sc-6199, 1:1000).
Secondary antibodies were purchased from Jackson Immuno Research Labs (West
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Grove, PA): Cy3 AffiniPure Goat Anti-Rabbit IgG (H+L) (111-165-144, 1:500) and Cy3
AffiniPure Donkey Anti-Goat IgG (H+L) (705-166-147, 1:500). Primary antibodies were
diluted in 0.1 M phosphate buffered saline (PBS) containing either 1% goat or donkey
serum.
Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)
Female Wistar rats (n=5-7 per condition) were anaesthetized with 2% isoflurane
and urinary bladders were harvested under RNase-free conditions following a
thoracotomy. Components of the urinary bladder (urothelium and detrusor smooth
muscle) were separated as previously described (9, 32). For transcript analyses, the term
urothelium refers to both the urothelial cell layers (basal, intermediate and apical) and
accompanying suburothelial structures. Total RNA was extracted from urothelium and
detrusor smooth muscle using STAT-60 total RNA/mRNA isolation reagent (Tel-Test
‘B’, Friendswood, TX) and complementary DNA (cDNA) was synthesized using random
hexamer and oligo dT primers with M-MLV reverse transcriptase (Promega Corp,
Madison, WI) (20). cDNA templates were assayed using HotStart-IT SYBR Green
qPCR Master Mix (USB Corporation, Cleveland, Ohio) containing 5 mM MgCl2, 0.4
mM dATP, dGTP, dCTP and dTTP, HotStart-IT Taq DNA polymerase and 300 nM of
each primer (Table 1) in a final 25 µL reaction volume (3, 20, 32). qRT-PCR was
performed on an Applied Biosystems 7500 Fast real-time PCR system (Foster City, CA)
using previously defined conditions (3, 20, 32). Amplicons were subjected to a SYBR
Green I melting curve analysis by ramping the reaction temperature from 60˚C to 95˚C.
A single hyperchromic effect was observed under these dissociation conditions
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demonstrating amplification of a specific product free of primer-dimers or other
contaminants.
Analysis: Data were analyzed at the termination of each assay using the
Sequence Detection Software (version 1.3.1; Applied Biosystems, Norwalk, CT). A
standard curve was constructed by amplification of serially diluted plasmids containing
the target sequence. The increase in SYBR Green I fluorescence intensity (ΔRn) was
plotted as a function of cycle number and the threshold cycle (CT) was the amplification
cycle at which ΔRn intersects baseline (3, 20, 32). qRT-PCR data are expressed as
relative quantity of the gene of interest normalized to the relative quantity of the
ribosomal reference gene, L32 (19).
Enzyme-Linked Immunosorbent Assays (ELISAs)
Female Wistar rats (n=8 per condition) underwent the aforementioned CYP
treatment and tissue harvest. Individual whole urinary bladders were weighed and
solubilized for immunoassays in tissue protein extraction (Pierce Biotechnology,
Woburn, MA) solution, a mild zwitterionic dialyzable detergent, supplemented with a
complete protease inhibitor cocktail (Roche, Indianapolis, IN) (36). Tissue was
homogenized using a Kinematica Polytron homogenizer (Fischer Scientific, Pittsburgh,
PA) and centrifuged (3,000 rpm at 10°C for 10 min). Supernatant was removed and
protein was quantified according to manufacturer instructions using a Coomassie Plus
Protein Assay Kit (Pierce Biotechnology).
Ninety-six (96)-well microtiter plates (R&D Systems, Minneapolis, MN) were
coated overnight with a capture antibody specific to the analyte (DuoSet Development
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Systems, R&D Systems). Plates were washed (1X PBS with 0.05% Tween20), blocked
(1X PBS with 5% Tween20) and then standards and samples were added in duplicate.
Standards provided by the manufacturer consisted of a seven point standard curve (r2=
0.989-0.997) in Reagent Diluent (1% BSA in PBS) beginning at 2,000 pg/mL. Following
a 2 h incubation, standards and samples were vigorously washed three times (3x) and a
biotinylated detection antibody specific to the analyte was added and allowed to incubate
for 2 h. Plates were washed (3x) and a detection reagent (streptavidin-horseradish
peroxidase) was added and incubated for 20 min. Plates were washed (3x) and a
substrate solution (hydrogen peroxide and tetramethylbenzidine) was added. Following
20 min incubation, reactions were terminated with 2N sulfuric acid and the optical
density was read at 450 nm and 570 nm.
Analysis: Absorbance values were corrected for optical imperfections by
subtracting readings at 570 nm (49). Samples were diluted to bring absorbance values
onto the linear portion of the standard curve. Samples did not fall below the minimum
detection limits of the assay. Curve fitting of standards and sample were performed using
least-squares fit regression analysis (49).
Immunohistochemistry
Female Wistar rats (n=4 per condition) underwent the aforementioned CYP
treatment and tissue harvest. Urinary bladder tissue was immediately allowed to incubate
in 4% paraformaldehyde for 24 h at 4°C and was then transferred to 30% sucrose in 0.1
M PBS overnight at 4°C. Tissue was embedded in optimal cutting temperature
compound (Tissue-Tek, Batavia, IL), sectioned at 20 µm and mounted on 0.5% gel65

coated slides (5, 9, 11). Sections were incubated overnight in polyclonal primary
antibody (rabbit anti-TGF-β1, rabbit anti-TβR-1, rabbit anti-TβR-2 and goat anti-TβR-3),
washed (3 x 10 min) and then incubated in Cyanine 3 (Cy3) AffiniPure conjugated
secondary antibody for 2 h. Following washing (3 x 10 min), slides were mounted with
an anti-fading media (Citifluor, Fischer Scientific) and coverslipped.
Visualization and semi-quantitative analysis: Immunoreactivity was captured
using an Olympus fluorescent photomicroscope with a charge-coupled device (CCD)
camera (MagnaFire SP, Optical Analysis, Nashua, NH) and LG-3 frame grabber (Scion,
Frederick, MD). Each experimental series was processed on the same day with exposure
time, brightness and contrast held constant throughout image acquisition (5, 9). To
visualize Cy3, the filter was set with an excitation range of 560-569 nm and an emission
range of 610-655 nm (5, 9). Images (6 per animal) were acquired, saved as 24-bit RGB
tagged image file format and imported into MetaMorph Image Analysis Software
(v4.5r4, Microscope Imaging Center, Downingtown, PA) (5, 9).
The focus of our analyses was on the urothelium and detrusor smooth muscle
whereas other parts of the lower urinary tract including the suburothelial plexus and
lumbosacral dorsal root ganglia (DRG) are the focus of a separate study. A free hand
drawing tool was used to trace and measure total pixels area in the urothelium (basal,
intermediate, apical) and excluded any suburothelial structures (11). For the detrusor
smooth muscle, six rectangles of fixed dimensions (125 x 125 pixels) were placed
without overlap according to random x and y coordinates (9, 32). As previously
described (9, 32), a threshold encompassing an intensity range of 100-250 grayscale
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values was applied to the region of interest in the least immunoreactive condition first
and was maintained throughout the series. The threshold was adjusted for each
experimental series with negative controls as a guide for setting background fluorescence
(9, 32).
Assessment of immunoreactivity: Immunohistochemistry and evaluation of TGFβ1 and TβR (1, 2 and 3) immunoreactivity in urothelium or detrusor smooth muscle were
performed on control and experimental tissues simultaneously to reduce the incidence of
staining variation that can occur between tissues processed on different days (5, 9, 11).
Staining in experimental tissue was compared with that in experiment-matched negative
controls. Negative controls following the same experimental procedures were processed
in the absence of a polyclonal primary antibody to assess specificity and background
staining. In the absence of primary antibody, positive immunoreactivity was not
observed (data not shown). Immunoreactivity was considered positive only when
intensity measurements of the target exceeded the established threshold. Percent
immunoreactivity above threshold as a function of total area selected was calculated and
reported. For the detrusor smooth muscle, percent target expression above threshold was
averaged across the six regions.
Cystometry
Intravesical Catheter Implant: A dorsal (below scruff of the neck) incision and
lower midline abdominal incision was performed under 2% isoflurane using aseptic
techniques. The end of a polyethylene (PE-50; Clay Adams, Parsippany, NJ) tube was
flared, tunneled and inserted into the bladder dome. The proximal end was secured to the
67

dome with a 6-0 nylon purse-string suture whereas the distal end was sealed, coiled and
stored in a dorsal subcutaneous pouch. Adult female Wistar rats (n=4-5 per condition)
recovered for 72 h with post-operative analgesia (Buprenorphine, 0.05 mg/kg, s.c.) being
maintained for 48 h. No animals met our exclusion criteria (3, 5).
Conscious, freely moving cystometry with an open outlet: The dorsal
subcutaneous polyethylene tubing was externalized under 2% isoflurane and the animal
was placed unrestrained into a Small Animal Cystometry System (Med Associates, St.
Albans, VT) recording cage over a scale and pan used to quantify voided volume.

The

animals were each given a 10 min acclimation period prior to the continuous intravesical
infusion of 0.9% sodium chloride (NaCl) injection, USP (Baxter, Deerfield, IL) at a rate
of 10 mL/h. To avoid micturition variation resulting from circadian rhythms, functional
tests were conducted at similar times of the day (15). Each animal was run for at least six
reproducible micturition cycles (pre-drug baseline) after an initial stabilization period (30
min). Intravesical pressure (non-voiding, filling, threshold and peak micturition
pressures), intercontraction interval and infused and voided volume were recorded for
each micturition cycle. Bladder capacity was quantified as the total infused 0.9% NaCl at
the time micturition commenced (3, 5). Non-voiding bladder contractions were defined
as rhythmic intravesical pressure increases 0.69 kilopascals (kPa) above baseline without
the release of fluid from the urethra and are not reported due to their infrequency in the
current study (3, 5).
To determine the role of TGF-β on urinary bladder function in control (no
inflammation) or CYP-treated rats, we intravesically instilled 1 mL of a TβR-1 small
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molecule inhibitor, SB505124 (5 µM; R&D Systems), under 2% isoflurane for 30 min
immediately following the baseline measurements. SB505124 (5 µM) was chosen due to
its in vitro potency and selectivity for TGF-β activated activin receptor-like kinases
(ALKs) (12). Intravesical instillation of 1 mL 0.01% dimethyl sulfoxide (DMSO) in
0.9% NaCl under 2% isoflurane was used for the vehicle control conditions. Rats
remained anesthetized during instillation to suppress the micturition reflex and prevent
expulsion of SB505124 (5 µM) or 0.01% DMSO (2, 3, 5). At the conclusion of drug
instillation, urinary bladder function tests were repeated and ran for at least 6
reproducible micturition cycles (post-drug). The animals were euthanized following
functional testing as described above.
Materials
SB505124 (R&D Systems) was reconstituted in DMSO (99.5%) and stored at 20°C. Prior to its use, stock solutions were diluted to a working concentration (5 μM)
with 0.9% NaCl injection, USP (Baxter).
Statistical Analyses
All values represent mean ± SEM. Data were compared with one-way or
repeated measures analysis of variance (ANOVA) where appropriate. When F(test
statistic) exceeded the critical value (p ≤ 0.05), the Bonferroni or Newman-Keuls
multiple comparisons test was used to compare group means.
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Results
TGF-β (1, 2 and 3) and TβR (1, 2 and 3) transcript expression in urothelium and detrusor
smooth muscle following CYP-induced cystitis.
The regulation of TGF-β (1, 2 and 3) and TβR (1, 2 and 3) transcripts in
urothelium and detrusor smooth muscle was examined by qRT-PCR analyses (Figure 1,
A-F).
TGF-β1
TGF-β1 transcript expression significantly increased relative to control in the
urothelium (p ≤ 0.001) and detrusor smooth muscle (p ≤ 0.01) following intermediate (48
h) CYP-induced cystitis (Figure 1A). Significant differences were not observed in
urothelium or detrusor smooth muscle following acute (4 h) or chronic CYP-induced
cystitis (Figure 1A).
TGF-β2
Basal TGF-β2 transcript expression significantly (p ≤ 0.05) differed between
urothelium and detrusor smooth muscle under control conditions (Figure 1B). TGF-β2
transcript expression in the urothelium significantly increased relative to control
following intermediate (48 h; p ≤ 0.01) or chronic (p ≤ 0.01) CYP-induced cystitis;
whereas, no significant differences were observed following acute (4 h) CYP-induced
cystitis (Figure 1B). Acute (4 h), intermediate (48 h) or chronic CYP-induced cystitis did
not significantly regulate TGF-β2 transcript expression in the detrusor smooth muscle
(Figure 1B).
TGF-β3
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TGF-β3 transcript expression significantly increased in the urothelium following
intermediate (48 h; p ≤ 0.001) or chronic (p ≤ 0.05) CYP-induced cystitis relative to
control; whereas, no significant differences were observed following acute (4 h) CYPinduced cystitis (Figure 1C). Acute (4 h), intermediate (48 h) or chronic CYP-induced
cystitis did not significantly regulate TGF-β3 transcript expression in the detrusor smooth
muscle (Figure 1C).
TβR-1
TβR-1 transcript expression significantly increased relative to control in the
urothelium following intermediate (48 h; p ≤ 0.01) or chronic (p ≤ 0.001) CYP-induced
cystitis (Figure 1D). In the detrusor smooth muscle, significant increases in TβR-1
transcript expression were only observed following chronic (p ≤ 0.05) CYP-induced
cystitis relative to control (Figure 1D). Significant differences in detrusor smooth muscle
TβR-1 transcript expression were not observed following acute (4 h) or intermediate (48
h) CYP-induced cystitis (Figure 1D).
TβR-2
Intermediate (48 h) CYP-induced cystitis significantly increased TβR-2
transcript expression in both the urothelium (p ≤ 0.05) and detrusor smooth muscle (p ≤
0.05); whereas, significant transcript increase following chronic CYP-induced cystitis
was only seen in the urothelium (p ≤ 0.001) (Figure 1E). Acute (4 h) CYP-induced
cystitis did not significantly regulate urothelial or detrusor smooth muscle TβR-2
transcript expression (Figure 1E).
TβR-3
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TβR-3 transcript expression significantly increased relative to control in the
urothelium following intermediate (48 h; p ≤ 0.001) and chronic (p ≤ 0.05) CYP-induced
cystitis (Figure 1F). Significant transcript increases were similarly seen in the detrusor
smooth muscle following intermediate (48 h; p ≤ 0.05) and chronic (p ≤ 0.05) CYPinduced cystitis (Figure 1F). Acute (4 h) CYP-induced cystitis did not significantly
regulate TβR-3 transcript expression in the urothelium or detrusor smooth muscle (Figure
1F).
TGF-β (1, 2 and 3) protein expression in whole urinary bladder following CYP-induced
cystitis.
The regulation of TGF-β (1, 2 and 3) urinary bladder protein was examined by
ELISAs (Figure 2, A-C). The selection of analyte was limited by commercial
availability. Intermediate (48 h) CYP-induced cystitis significantly increased urinary
bladder TGF-β1 (p ≤ 0.001) and TGF-β3 (p ≤ 0.05) protein expression relative to control
(Figure 2, A and C). Significant differences relative to control were not observed in
TGF-β1 and TGF-β3 urinary bladder protein expression following acute (4 h) or chronic
CYP-induced cystitis (Figure 2, A and C). TGF-β2 urinary bladder protein expression did
not significantly differ relative to control across acute (4 h), intermediate (48 h) or
chronic CYP treatments (Figure 2B).
TGF-β1 and TβR (1, 2 and 3) immunoreactivity (IR) in urothelium and detrusor smooth
muscle following CYP-induced cystitis.
Based on the transcriptional and translational expression profiles observed, we
focused immunostaining on TGF-β1 and TβR variants whose mRNA and protein
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exhibited tissue and temporal regulation by CYP treatment (Figure 1A, 1D, 1E, 1F and
Figure 2A). Regional differences in IR were not observed in the dome, body or neck of
the rat urinary bladder.
TGF-β1
Low-intensity, basal TGF-β1-IR was present in all urothelial layers (basal,
intermediate and apical) and detrusor smooth muscle of control rat urinary bladders
(Figure 3, A and E). Acute (4 h) CYP-induced cystitis revealed no observable
differences in urothelial or detrusor smooth muscle TGF-β1-IR relative to control (Figure
3, B and F). Intermediate (48 h) or chronic CYP-induced cystitis, however, resulted in a
high-intensity TGF-β1-IR in both the urothelium and detrusor smooth muscle (Figure 3,
C-D and G-H). Semi-quantitative analyses revealed a significant suprathreshold increase
relative to control in the urothelium following intermediate (48 h; p ≤ 0.001) or chronic
(p ≤ 0.001) CYP-induced cystitis (Figure 3I). Similarly, semi-quantitative analyses in the
detrusor smooth muscle revealed a significant suprathreshold increase relative to control
following intermediate (48 h; p ≤ 0.01) or chronic (p ≤ 0.01) CYP-induced cystitis
(Figure 3J).
TβR-1
Low-intensity, basal TβR-1-IR was present in all urothelial layers (basal,
intermediate and apical) and detrusor smooth muscle of control rat urinary bladders
(Figure 4, A and E). Acute (4 h) CYP-induced cystitis resulted in moderate urothelial IR
relative to control, whereas intermediate (48 h) or chronic CYP-induced cystitis resulted
in a high-intensity urothelial TβR-1-IR (Figure 4, B-D). Semi-quantitative analyses
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revealed a significant suprathreshold increase relative to control in the urothelium
following intermediate (48 h; p ≤ 0.001) or chronic (p ≤ 0.01) CYP-induced cystitis
(Figure 4I). There were no observable differences in detrusor smooth muscle TβR-1-IR
following acute (4 h) CYP-induced cystitis, while intermediate (48 h) or chronic CYPinduced cystitis resulted in moderate IR relative to control (Figure 4, F-H). Semiquantitative analyses revealed an emerging trend of robust suprathreshold IR following
intermediate (48 h) or chronic CYP-induced cystitis (Figure 4J).
TβR-2
Low-intensity, basal TβR-2-IR was present in all urothelial layers (basal,
intermediate and apical) and detrusor smooth muscle of control rat urinary bladders
(Figure 5, A and E). Acute (4 h) CYP-induced cystitis resulted in moderate urothelial
and detrusor smooth muscle IR relative to control, while intermediate (48 h) or chronic
CYP-induced cystitis resulted in a high-intensity TβR-2-IR (Figure 5, B-D and F-H).
Semi-quantitative analyses revealed a significant suprathreshold increase relative to
control in the urothelium following intermediate (48 h; p ≤ 0.001) or chronic (p ≤ 0.01)
CYP-induced cystitis (Figure 5I). Similarly, semi-quantitative analyses in the detrusor
smooth muscle revealed a significant suprathreshold increase relative to control following
intermediate (48 h; p ≤ 0.001) or chronic (p ≤ 0.01) CYP-induced cystitis (Figure 5J).
TβR-3
Low-intensity, basal TβR-3-IR was present in the detrusor smooth muscle of
control rat urinary bladders (Figure 6A). Acute (4 h) CYP-induced cystitis resulted in
moderate IR relative to control, while intermediate (48 h) or chronic CYP-induced
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cystitis resulted in a high-intensity detrusor smooth muscle TβR-3-IR (Figure 6, B-D).
Semi-quantitative analyses revealed a significant suprathreshold increase relative to
control in the detrusor smooth muscle following intermediate (48 h; p ≤ 0.01) or chronic
(p ≤ 0.01) CYP-induced cystitis (Figure 6E). TβR-3-IR was not present in the urothelium
following any control or CYP treatment paradigm (data not shown).
Urinary bladder function following TβR-1 inhibition in control (no inflammation) or
intermediate (48 h) CYP-induced cystitis rats.
Urinary bladder function was determined using open outlet, continuous
cystometry in conscious, freely moving control or intermediate (48 h) CYP-induced
cystitis rats (Table 2). Intermediate (48 h) CYP-induced cystitis was chosen for analysis
due to a robust increase in urinary bladder TGF-β ligand and receptor transcript and
protein expression.
Control (no inflammation)
Intravesical instillation of SB505124 (5 µM) significantly (p ≤ 0.05) decreased
voiding frequency and increased bladder capacity (1.3-fold), void volume (1.4-fold) and
intercontraction intervals (1.3-fold) relative to pre-drug baseline measurements (Table 2).
Intravesical pressure (filling, threshold, peak) was not significantly affected following
SB505124 (5 µM) instillation (Table 2). Residual volume before or after SB505124 (5
µM) instillation was minor (≤ 35 µL) and the effects of treatment persisted throughout
the entirety of the experiment (1.5-2 h).
Intermediate (48 h) CYP-induced cystitis
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As previously demonstrated (3, 5, 29), intermediate (48 h) CYP-induced cystitis
increased voiding frequency and intravesical pressure (filling, threshold, peak) and
decreased bladder capacity, void volume and intercontraction intervals relative to control
(no inflammation) rats (Table 2). Intravesical instillation of SB505124 (5 µM)
significantly (p ≤ 0.001) decreased voiding frequency and increased bladder capacity
(2.5-fold), void volume (2.6-fold) and intercontraction intervals (2.5-fold) relative to predrug baseline measurements (Table 2, Figure 7). SB505124 (5 µM) did not significantly
affect intravesical pressure (filling, threshold, peak) in CYP-treated (48 h) rats (Table 2,
Figure 7). Residual volume before or after SB505124 (5 µM) instillation was minor (≤
20 µL) and the effects of treatment persisted throughout the entirety of the experiment
(1.5-2 h).
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Discussion
The present study characterized the expression of urinary bladder TGF-β (1, 2
and 3) and TβR (1, 2 and 3) following CYP-induced cystitis of varying durations and
established a role for TGF-β signaling in micturition reflex function. We confirmed the
presence of a delayed TGF-β proinflammatory phenotype following acute urinary bladder
inflammation and extended previous findings (45, 55) by demonstrating the functional
expression and chronicity of urinary bladder TGF-β. These results provide evidence for a
novel molecular component of the urinary bladder inflammatory response that, when
inhibited, reduces voiding frequency with urinary bladder dysfunction.
The expression of TGF-β ligands in the urinary bladder proinflammatory
cytokine milieu has been previously suggested to reflect the inflammatory state of the
urinary bladder (55). Zhang and Qiao (2012) have observed a step-wise TGF-β1
transcript upregulation following acute (8 h) and intermediate (48 h) CYP-induced
cystitis, while Tyagi et al. (2009) observed significant upregulation of TGF-β1 urinary
bladder protein following acute (24 h) CYP-induced cystitis. Similarly, the present study
demonstrates an upregulation of TGF-β ligand and receptor expression following
intermediate (48 h) or chronic CYP-induced cystitis, but not acute (4 h) CYP-induced
cystitis. The temporal regulation of TGF-β transcript and protein expression may aid in
monitoring the urinary bladder inflammatory response and suggests an involvement in
the resolution of urinary bladder inflammation to initiate tissue remodeling (45).
In the remedial stages of inflammation, the urinary bladder undergoes alterations
characterized by a deposition of extracellular matrix constituents and proliferation of
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activated fibroblasts (13). Although the precise contribution of TGF-β to pathological
tissue remodeling is unknown, TGF-β is capable of promoting deposition of profibrotic
extracellular matrix proteins and preventing matrix degradation by inhibiting expression
of metalloproteinases and plasminogen-activators (8). While neither the present nor past
studies address the role of TGF-β in urinary bladder remodeling, our results suggest the
profibrotic profile may be partly mediated by a delayed, long lasting TGF-β upregulation.
Chronic urinary bladder inflammation is characterized by increased
mononuclear cell infiltration, mucosal ulceration and the systemic release of
proinflammatory cytokines and chemokines from distinct tissue compartments (40, 42).
The present study not only demonstrated the temporal regulation of TGF-β but also the
differential distribution of TGF-β ligands and its cognate receptors. The regulation of
TGF-β1 and TGF-β3 transcript expression in the urothelium appeared to contribute most
to the global translational profiles observed in our conditions. However, significant
upregulation of TGF-β2 transcript in the urothelium was not sufficient to increase urinary
bladder protein at any CYP-treatment duration. These differences may reflect the
elevated basal TGF-β2 transcript expression in the detrusor smooth muscle relative to the
urothelium. TβR (1, 2 and 3) transcript expression in the urothelium and detrusor smooth
muscle was, in general, significantly increased following intermediate (48 h) or chronic
CYP-induced cystitis. These profiles were maintained in TβR-1 and TβR-2 antigen
immunoreactivity in the urothelium, as well as TβR (1, 2 and 3) immunoreactivity in the
detrusor smooth muscle. The absence of urothelial TβR-3 immunoreactivity in control or
CYP-treated animals may reflect transcript expression and regulation in the
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suburothelium, transcript instability (27), decreased translation efficiency and/or
increased receptor internalization (17).
While the clinical presentation of IC/BPS is diverse, there remain
histopathologic and immunologic features that may contribute to urinary bladder
dysfunction. Cystoscopic and bladder biopsy examinations indicate IC/BPS patients may
present with a constellation of signs and symptoms including: an exaggerated
inflammatory response, intrafascicular fibrosis and detrusor mastocytosis (37, 39, 46).
Our findings combined with the established role of TGF-β in cellular proliferation,
differentiation and migration, suggests TGF-β ligand overexpression and subsequent
intracellular signaling may contribute, in part, to the pathophysiology of our experimental
cystitis model of IC/BPS. To determine if aberrant TGF-β signaling contributes to
urinary bladder dysfunction, we intravesically instilled a competitive ATP small
molecule inhibitor, SB505124 (5 µM). Due to the structural similarities between TGF-β
activated ALKs, it is possible for SB505124 to have off target effects on activin A
receptor, type IB (ACVR1B, ALK4). While further studies are necessary to define the
specific role(s) of ACVR1B and TβR-1 on urinary bladder dysfunction, SB505124
demonstrates 2.5-fold less potency in vitro on ACVR1B SMAD phosphorylation
suggesting it may have a greater influence on TGF-β signaling in vivo (12, 51).
Instillation of SB505124 (5 µM) decreased voiding frequency in both control
(no inflammation) and intermediate (48 h) CYP-induced cystitis rats, however,
differences in fold change suggest TGF-β signaling has a more prominent role in
micturition reflex function following urinary bladder inflammation. These results not
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only remain consistent with the transcriptional and translational overexpression profiles
observed following intermediate (48 h) CYP-induced cystitis but also demonstrate a
novel, albeit small, role for TGF-β in normal micturition reflex function.
Cystometrogram recordings in control (no inflammation) rats following SB505124 (5
µM) instillation revealed a role for basal urothelial TGF-β signaling in micturition reflex
function due to the barrier properties provided by intact junction complexes and
specialized apical proteins (4). In addition, the absence of intravesical pressure changes
suggests little to no effect on the urethral outlet and efferent limb of the micturition
reflex. Similar parameters (void frequency, infused and voided volume, intercontraction
intervals) were altered following intermediate (48 h) CYP-induced cystitis and SB505124
(5 µM) suggesting a role for aberrant TGF-β signaling in the afferent limb of the
micturition reflex. Specific tissues or cell types in the urinary bladder that contribute to
the functional effects are less clear due to increases in urinary bladder permeability after
CYP metabolism (16) and global TβR-1 overexpression. Future studies can address
suburothelial-specific overexpression of TβR-1 and/or determine the contributions of
urothelial and detrusor smooth muscle TGF-β signaling to resolve our observed
phenotypes.
The combination of systemic proinflammatory cytokine release, mononuclear
cell infiltration and the profibrotic resolution of inflammation may contribute to
peripheral and central sensitization that may facilitate viscerosomatic hypersensitivity
and bladder hyperreflexia observed in IC/BPS (42). Given the biological contributions
TGF-β may have on urinary bladder dysfunction (45, 55) and its recently established role
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in peripheral sensitization (56), the present study characterized TGF-β transcript and
protein expression at the level of the urinary bladder and provided evidence for a
functional role of TGF-β signaling in the afferent limb of the micturition reflex. These
studies demonstrate that targeting one component of the urinary bladder inflammatory
response may be an effective strategy to reduce voiding frequency in an experimental
cystitis model of IC/BPS.
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Table 1: Primer sequences
rTGF-β, Rat Transforming Growth Factor-Beta;
rTβR, Rat Transforming Growth Factor-Receptor.
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Table 2: Cystometrogram recordings for control (no inflammation) or
intermediate (48 h) CYP-induced cystitis rats with SB505124 (5 µM) or 0.01%
DMSO instillation
Intravesical instillation of SB505124 (5 µM) significantly decreased voiding frequency
and increased bladder capacity (total infused 0.9% NaCl at the time micturition
commenced), void volume and intercontraction intervals relative to pre-SB505124
baseline measurements in both control (no inflammation) and intermediate (48 h) CYPinduced cystitis rats. n=4-5 per condition; values are mean ± SEM; *p ≤ 0.05, ***p ≤
0.001 versus pre-SB505124 baseline.
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Figure 1: Time- and tissue-dependent regulation of TGF-β (1, 2 and 3) and TβR (1, 2 and 3)
transcript expression following cyclophosphamide (CYP) treatment
TGF-β (1, 2 and 3) and TβR (1, 2 and 3) transcript expression was not significantly regulated following
acute (4 h) induced cystitis. Intermediate (48 h) CYP-induced cystitis significantly increased TGF-β1 (A;
urothelium/detrusor smooth muscle), TGF-β2 (B; urothelium), TGF-β3 (C; urothelium), TβR-1 (D;
urothelium), TβR-2 (E; urothelium/detrusor smooth muscle) and TβR-3 (F; urothelium/detrusor smooth
muscle) transcript expression relative to control. Chronic CYP-induced cystitis significantly increased
TGF-β2 (B; urothelium), TGF-β3 (C; urothelium), TβR-1 (D; urothelium/detrusor smooth muscle), TβR-2
(E; urothelium) and TβR-3 (F; urothelium/detrusor smooth muscle) transcript expression relative to control.
n=5-7 per condition; values are mean ± SEM; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 versus control.
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Figure 2: Time-dependent regulation of TGF-β (1, 2 and 3) protein expression in whole rat urinary
bladder following CYP treatment
(A) TGF-β1 urinary bladder protein expression was significantly increased following intermediate (48 h)
CYP-induced cystitis. (B) TGF-β2 urinary bladder protein expression did not significantly differ across any
condition relative to control. (C) TGF-β3 urinary bladder protein expression was significantly increased
following intermediate (48 h) CYP-induced cystitis. n=8 per condition; values are mean ± SEM; *p ≤ 0.05,
***p ≤ 0.001 versus control.
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Figure 3: Time- and tissue-dependent regulation of TGF-β1 immunoreactivity (IR) following CYP
treatment
(A-D) Representative images of TGF-β1-IR in urothelium following control or CYP treatment paradigms.
(E-H) Representative images of TGF-β1-IR in detrusor smooth muscle following control or CYP treatment
paradigms. (I) Semi-quantitative analyses in urothelium revealed a significant suprathreshold increase
following intermediate (48 h) or chronic CYP-induced cystitis. (J) Semi-quantitative analyses in detrusor
smooth muscle revealed a significant suprathreshold increase following intermediate (48 h) or chronic
CYP-induced cystitis. L, lumen; U, urothelium; SU, suburothelium; sm, detrusor smooth muscle.
Figure 3: Time- and tissue-dependent regulation of TGF-β1 immunoreactivity (IR) following CYP
treatment.
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Figure 4: Time- and tissue-dependent regulation of TβR-1 immunoreactivity (IR) following CYP
treatment
(A-D) Representative images of TβR-1-IR in urothelium following control or CYP treatment paradigms.
(E-H) Representative images of TβR-1-IR in detrusor smooth muscle following control or CYP treatment
paradigms. (I) Semi-quantitative analyses in urothelium revealed a significant suprathreshold increase
following intermediate (48 h) or chronic CYP-induced cystitis. (J) Semi-quantitative analyses in detrusor
smooth muscle revealed a robust suprathreshold trend following intermediate (48 h) or chronic CYPinduced cystitis. L, lumen; U, urothelium; SU, suburothelium; sm, detrusor smooth muscle. Calibration
bar represents 25 µm. n=4 per condition; values are mean ± SEM; **p ≤ 0.01, ***p ≤ 0.001 versus control.
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Figure 5: Time- and tissue-dependent regulation of TβR-2 immunoreactivity (IR) following CYP
treatment
(A-D) Representative images of TβR-2-IR in urothelium following control or CYP treatment paradigms.
(E-H) Representative images of TβR-2-IR in detrusor smooth muscle following control or CYP treatment
paradigms. (I) Semi-quantitative analyses in urothelium revealed a significant suprathreshold increase
following intermediate (48 h) or chronic CYP-induced cystitis. (J) Semi-quantitative analyses in detrusor
smooth muscle revealed a significant suprathreshold increase following intermediate (48 h) or chronic
CYP-induced cystitis. L, lumen; U, urothelium; SU, suburothelium; sm, detrusor smooth muscle.
Calibration bar represents 25 µm. n=4 per condition; values are mean ± SEM; **p ≤ 0.01, ***p ≤ 0.001
versus control.
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Figure 6: Time- and tissue-dependent regulation of TβR-3 immunoreactivity (IR) following CYP
treatment
(A-D) Representative images of TβR-3-IR in detrusor smooth muscle following control or CYP treatment
paradigms. (E) Semi-quantitative analyses in detrusor smooth muscle revealed a significant suprathreshold
increase following intermediate (48 h) or chronic CYP-induced cystitis. L, lumen; U, urothelium; SU,
suburothelium; sm, detrusor smooth muscle. Calibration bar represents 25 µm. n=4 per condition; values
are mean ± SEM; **p ≤ 0.01 versus control.
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Figure 7: Cystometrogram traces of TβR-1 inhibition following intermediate (48 h) CYP-induced
cystitis
(A) Representative pre-SB505124 baseline traces. (B) Representative post-SB505124 (5 µM) traces.
Intravesical instillation of SB505124 (5 µM; B) significantly (p ≤ 0.001) decreased voiding frequency and
increased bladder capacity (total infused 0.9% NaCl at the time micturition commenced; 2.5-fold), void
volume (2.6-fold) and intercontraction intervals (2.5-fold) relative to pre-SB505124 baseline measurements
(A). Representative traces (A, B) were from the same rat.
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CHAPTER 3: PURINERGIC SIGNALING UNDERLIES TRANSFORMING
GROWTH FACTOR-BETA MEDIATED BLADDER AFFERENT NERVE
HYPEREXCITABILITY

Eric J. Gonzalez, Thomas J. Heppner, Mark T. Nelson, and Margaret A. Vizzard
J Physiol., submitted on 10/27/2015
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Key Points


The sensory components of the urinary bladder are responsible for the
transduction of bladder filling and are often impaired with neurological injury or
disease.



Elevated extracellular ATP contributes, in part, to bladder afferent nerve
hyperexcitability during neurogenic bladder inflammation or irritation.



TGF-β1 stimulates ATP release from the urothelium through vesicular exocytosis
mechanisms with minimal contribution from pannexin-1 channels to increase
bladder afferent nerve discharge.



Bladder afferent nerve hyperexcitability and urothelial ATP release with CYPinduced cystitis is decreased with TGF-β inhibition.



These results establish a causal link between an inflammatory mediator, TGF-β,
and intrinsic signaling mechanisms of the urothelium that may contribute to the
altered sensory processing of bladder filling.
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Abstract
The afferent limb of the micturition reflex is often compromised following bladder
injury, disease and inflammatory conditions. We have previously demonstrated that
transforming growth factor-beta (TGF-β) signaling contributes to increased voiding
frequency and decreased bladder capacity with cystitis. Despite the functional presence of
TGF-β in bladder inflammation, the precise mechanisms of TGF-β mediating bladder
dysfunction are not yet known. Thus, the present studies investigated the sensory
components of the urinary bladder that may underlie the pathophysiology of aberrant
TGF-β activation. We utilized bladder-pelvic nerve preparations to characterize bladder
afferent nerve discharge and the mechanisms of urothelial ATP release with distention.
Our findings indicate that bladder afferent nerve discharge is sensitive to elevated
extracellular ATP during pathological conditions of neurogenic bladder inflammation or
irritation. We determined that TGF-β1 increased bladder afferent nerve excitability by
stimulating ATP release from the urothelium via vesicular exocytosis mechanisms with
minimal contribution from pannexin-1 channels. Furthermore, blocking aberrant TGF-β
signaling in cyclophosphamide-induced cystitis with TβR-1 inhibition decreased afferent
nerve hyperexcitability with a concomitant decrease in urothelial ATP release. Taken
together, these results establish a role for purinergic signaling mechanisms in TGF-β
mediated bladder afferent nerve activation that may ultimately facilitate increased
voiding frequency. The synergy between intrinsic urinary bladder signaling mechanisms
and an inflammatory mediator provides novel insight into bladder dysfunction and
supports new avenues for therapeutic intervention.
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Abbreviations. BFA, Brefeldin A; CYP, cyclophosphamide; Det, detrusor smooth
muscle; ICC, interstitial cells of Cajal; P2X/P2Y, purinergic receptor; Panx1, pannexin 1;
PPADS, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid; PSS, physiological saline
solution; TGF-β, transforming growth factor-beta; TβR, transforming growth factor-β
receptor.
Keywords: urinary bladder, TGF-β, ATP, inflammation
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Introduction
The transitional epithelial cells that line the bladder lumen are now recognized
to act as a passive barrier to urinary metabolites (Min et al., 2003) and contribute to the
sensory transduction of bladder filling (Birder, 2005). These cells, termed the urothelium,
respond to mechanical (Olsen et al., 2011) or chemical (Everaerts et al., 2010) stimuli by
releasing urinary proteins (Deng et al., 2001) or neuroactive signaling molecules
(Ferguson et al., 1997; Birder et al., 2002; Hanna-Mitchell et al., 2007; Nile & Gillespie,
2012) from their apical and basolateral surfaces (Lewis & Lewis, 2006). The release of
these mediators presumably permits the urothelium to communicate with nerve endings
(Morrison, 1999; Andersson, 2002) and other cell types such as interstitial cells of Cajal
(ICC) (Sui et al., 2008; Drumm et al., 2014) or smooth muscle cells (Hashitani et al.,
2004) that are proximal to the mucosa. Given the role that the urothelium has in bladder
sensation, any disruption to these signaling mechanisms, such as what may occur with
inflammation (de Groat & Yoshimura, 2009), may contribute to the development of
lower urinary tract symptoms (Gonzalez et al., 2014b).
Purinergic signaling has garnered much of the focus in bladder sensory
processing ever since the urothelium was discovered to release ATP (Ferguson et al.,
1997). The mechanisms of ATP release from the urothelium have since been
demonstrated to include vesicular exocytosis (Wang et al., 2005; Sui et al., 2014;
McLatchie & Fry, 2015), ion channels (Wang et al., 2005; Sui et al., 2014; Beckel et al.,
2015; McLatchie & Fry, 2015) and transporters (Wang et al., 2005). Extracellular ATP
and other associated nucleotides may then bind to purinergic receptors located on various
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cell types (e.g. urothelial (Tempest et al., 2004; Chopra et al., 2008), smooth muscle
(Heppner et al., 2005) and ICC (Wu et al., 2004)) or nerve terminals (Namasivayam et
al., 1999; Andersson, 2002) to activate autocrine or paracrine pathways and facilitate
bladder sensory signaling (Birder & Andersson, 2013). Purinergic signaling in these cell
types has been demonstrated to increase sensory neuron excitability (Chen et al., 1995)
and to modulate smooth muscle tone (Sui et al., 2014). Furthermore, aberrant purinergic
signaling in the urothelium has been suggested to contribute to bladder dysfunction in
injury or disease since ATP release is increased in many functional disorders of the
urinary bladder (Sun et al., 2001; Ruggieri, 2006; Sun & Chai, 2006; Silva-Ramos et al.,
2013).
In addition to alterations in the intrinsic properties of the urothelium, functional
disorders of the bladder that activate an inflammatory response may also involve an
upregulation of proinflammatory mediators (Gonzalez et al., 2014a). Previous studies
from our laboratory have established the roles of cytokines (Malley & Vizzard, 2002) and
chemokines (Arms et al., 2010; Arms et al., 2013) in the maintenance and development
of lower urinary tract symptoms. In particular, we have demonstrated that transforming
growth factor-beta (TGF-β) overexpression contributes to the afferent limb of the
micturition reflex with cyclophosphamide (CYP)-induced cystitis (Gonzalez et al., 2013).
In addition to its role(s) in cystitis, increased urinary TGF-β has also been observed in
diabetic nephropathy (Chen et al., 2003) and other nephropathic conditions (Goumenos et
al., 2002; De Muro et al., 2004) with bladder dysfunction (Golbidi & Laher, 2010).
Despite its functional presence in the bladder inflammatory milieu, the precise
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mechanisms of TGF-β mediating voiding dysfunction are not yet known. Therefore, we
hypothesized that TGF-β signaling contributes to afferent nerve excitability through
purinergic mechanisms that may ultimately facilitate increased voiding frequency. A
comprehensive understanding of the downstream signaling effectors that interact in the
afferent limb of the micturition reflex with bladder dysfunction will allow for novel
therapeutic approaches to improve the quality of life of these patients.
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Materials and Methods
Ethical Approval
Experimental procedures were approved by the University of Vermont
Institutional Animal Care and Use Committee (protocol 08-055) and experiments were
conducted in accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals (8th edn).
Animals
Male C57Bl/6 mice (3-6 months old) purchased from Jackson Laboratories (Bar
Harbor, ME) were housed with littermates and maintained in standard laboratory
conditions with food and water available ad libitum.
Induction of CYP-induced cystitis
Male C57Bl/6J mice (n=4) received a 150 mg/kg I.P. injection of CYP (SigmaAldrich, St. Louis, MO). Mice were harvested 48 h following CYP treatment for bladderpelvic nerve electrophysiology or ATP release experiments.
Bladder-pelvic nerve electrophysiology
The bladder-pelvic nerve model was developed and described in detail by
Namasivayam et al. (1998). Briefly, male C57Bl/6J mice (n=3-4) were euthanized by an
injection of pentobarbital sodium (I.P.) followed by decapitation. The abdominal cavity
was opened by a midline incision and the urinary bladder and surrounding tissues
(urethra, ureters, major pelvic ganglia, postganglionic nerves and pelvic nerves) were
excised and transferred to ice-cold dissection solution. The ureters were isolated,
dissected and ligated with nylon suture adjacent to the bladder wall. The pelvic nerves
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were isolated and the ends were cleaned of connective tissue to facilitate recording. The
urinary bladder, urethra, ureters and pelvic nerves were then transferred to a recording
chamber on a vibraplane platform and superfused with biological atmosphere gas (20%
O2, 5% CO2, 75% N2) physiological saline solution (PSS) circulating at 37 °C. One arm
of a triple lumen cannula was inserted through the urethra into the bladder and ligated.
The remaining arms were attached to a remote-controlled syringe pump and pressure
transducer to monitor intravesical pressure or used to empty the bladder. One of the
pelvic nerves was attached to a suction electrode to record distention-evoked multifiber
afferent nerve activity. With this recording arrangement, we did not identify the relative
contribution(s) of myelinated Aδ fibers and the normally quiescent umyelinated C fibers.
Vehicle or drugs were administered at a rate of 30 µl/min intravesically up to 25 mmHg
for the filling phase and then manually emptied. There was a 10 min rest period between
the emptying phase and the start of the next filling phase. For the co-administration
studies, bladders were first pretreated with the various inhibitors followed by the
inhibitors plus TGF-β1. Administration of drugs began once bladder afferent nerve
activity to the vehicle plateaued for two consecutive filling phases (usually after 5-6
filling cycles). Bladder afferent nerve activity was collected and amplified with a
Neurolog head stage (NL104, Digitimer), filtered (band pass 200-4000 Hz) using a
Digitimer NL125/Nl126 filter and digitized with a Power 1401 analog to digital interface
(Cambridge Electronic Design, Cambridge, UK). The acquisition rates for nerve activity
and bladder pressure were 25,000 Hz and 100 Hz, respectively. Data were analyzed
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offline via Spike 2 software (version 5.11, Cambridge Electronic Design, Cambridge,
UK).
Analysis: Action potentials were determined by using twice the root mean
square amplitude of the recording signal for detection threshold. Action potential events
were quantified in 5 mmHg increments to determine activity throughout multiple
pressures in the filling phase. The mean frequency (imp/sec) graphed for each condition
(vehicle or drug) per animal was the average of two consecutive filling phases. A twoway repeated measures ANOVA followed by Sidak’s multiple comparisons test was then
performed to compare these frequency group means. Fold change group means were
compared with Student’s unpaired t test.
ATP release
Male C57Bl/6J mice (n=4-8) were anesthetized with 2% isoflurane and
euthanized by decapitation. The abdominal cavity was opened by a midline incision and
the urinary bladder, urethra and ureters were excised and transferred to ice-cold
dissection solution. The ureters were isolated, dissected and ligated with nylon suture
adjacent to the bladder wall. The urinary bladder, urethra and ureters were then
transferred to a recording chamber with oxygenated (95% O2-5% CO2) PSS circulating
at 37 °C and cannulated through the urethra with a 22 gauge blunt needle. The cannula
was attached to a remote-controlled syringe pump and a pressure transducer to monitor
intravesical pressure. Vehicle or drugs were administered at a rate of 30 µl/min
intravesically up to 25 mmHg for the filling phase and then manually emptied via a threeway stop cock. There was a 10 min rest between the emptying phase and the start of the
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next filling phase. After 1-1.5 h of vehicle or drug administration, the instillate was
collected from two separate but consecutive emptying cycles and immediately flash
frozen until ATP analysis. Upon collection, CYP instillate samples also received
adenylyl-imidodiphosphate (AMP-PNP, 200 µM) to limit ATP hydrolysis that may be
present from a compromised barrier. ATP quantification was determined with the ATP
bioluminescent assay kit (Sigma-Aldrich, St. Louis, MO) following their procedural
instructions with the exception of halving the recommended concentration of reagents
and samples. ATP measurements were taken with the BioTek H4 Plate Reader
(Winooski, VT) within the UVM Advanced Genome Technologies Core.
Analysis: The bioluminescence emitted by the sample was plotted against the
calibration curve to determine the final concentration (pmol/ml) of ATP. Calibration
curves were not affected by the drugs used in the current study (data not shown).
Statistical analysis was performed on the ATP concentration (pmol/ml) of the instillate
before or after drug administration as Student’s paired t test for all group means.
Materials
The dissection solution consisted of (in mM) 55 NaCl, 6 KCl, 80 MSG, 10
HEPES, 2 MgCl2, 10 glucose, and adjusted to pH 7.3. The PSS consisted of (in mM) 119
NaCl, 4.7 KCl, 24 NaHCO3, 1.2 KH2PO4, 1.2 MgCl2, 2 CaCl2, 7 glucose, and adjusted
to pH 7.4. Recombinant mouse transforming growth factor-beta 1 (TGF-β1, R&D
Systems) was reconstituted to 50 µg/ml in 4 mM HCl and 0.1% BSA and stored at -20
°C. Bladder tissues respond to a range of TGF-β1 concentrations (Hiti et al., 1990; Duan
et al., 2015) and 10 ng/ml was selected for as the working concentration as it does not
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induce EMT related genes in the urothelium (Islam et al., 2014). SB505124 (R&D
Systems) was reconstituted to 100 mM in DMSO (99.5%) and stored at -20 °C.
SB505124 is a potent inhibitor of TGF-β type I receptor kinase activity with an IC50 of
47 ± 5 nM (DaCosta Byfield et al., 2004). Before its use, stock solutions were diluted to a
working concentration (5 µM) with PSS. Concentrations up to 5 μM maintain inhibition
specificity of downstream targets of TβR-1 and other closely related receptors and have
been demonstrated to decrease voiding frequency with cystitis (DaCosta Byfield et al.,
2004; Gonzalez et al., 2013). Brefeldin A (BFA, R&D Systems) was reconstituted to 50
mM in DMSO (99.5%) and stored at -20 °C. Stock solutions were diluted to a working
concentration (10 µM) with PSS to remain consistent with previous literature
demonstrating decreased ATP release from the urothelium (Sui et al., 2014; McLatchie &
Fry, 2015). 10Panx (R&D Systems) was reconstituted to 1 mg/ml in PSS and stored at 20 °C. The IC50 of 10Panx for the inhibition of panx1 currents in overexpressed panx1
HEK cells is 52 ± 12 μM (Pelegrin & Surprenant, 2006). We utilized 10Panx at a
working concentration of 50 μM because intravesical 10Panx near the IC50 concentration
was functional in the urinary bladder to decrease voiding frequency (Timoteo et al.,
2014). Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid tetrasodium salt (PPADS,
R&D Systems) was reconstituted to 100 mM in distilled water and stored protected from
light at -20 °C to prevent photodecomposition. A working concentration of 300 μM was
selected for PPADS because Vlaskovska et al. (2001) reported decreased distentionevoked afferent nerve discharge in control tissues that was not observed at lower
concentrations (Yu & de Groat, 2008).
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Statistics
All values represent means ± SEM. Outliers were identified using the extreme
studentized deviate test on GraphPad Prism (v. 6.07, La Jolla, CA) and excluded from
further analysis. Data were then compared with two-way repeated measures ANOVA and
two-tailed Student’s unpaired or paired t test where appropriate. When F-test statistic
exceeded the critical value at α = 0.05, the Sidak’s multiple comparisons test was used to
compare group means.
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Results
TGF-β1 increased bladder afferent nerve discharge and ATP release from the
urothelium.
The continuous intravesical instillation of recombinant TGF-β1 (10 ng/ml) had a
significant (p = 0.0447) treatment effect on mean bladder afferent nerve frequency
(imp/sec) (Figure 1A, Figure 1B). Nerve firing increased (50.5 ± 9.9 to 71.6 ± 13.3
imp/sec, n=4) by 41.8% from 0-25 mmHg with TGF-β1 instillation. More specifically,
nerve discharge significantly increased from 5-10 (p = 0.0337), 10-15 (p = 0.0003), 15-20
(p ≤ 0.0001) and 20-25 (p ≤ 0.0001) mmHg (Figure 1B). Distention-evoked ATP release
from the urothelium at 25 mmHg was also significantly (p = 0.0066) increased with the
intravesical instillation of TGF-β1 (Figure 1C).
The concurrent intravesical instillation of TGF-β1 and SB505124 (5 µM), a
TGF-β type I receptor inhibitor, attenuated (p = 0.4396) afferent nerve hyperexcitability
(76.8 ± 17.7 to 61.8 ± 12.9 imp/sec, n=4) from 0-25 mmHg (Figure 2C, Figure 2D).
SB505124 co-administration also attenuated (p = 0.3245) TGF-β1 mediated distentionevoked urothelial ATP release at 25 mmHg (Figure 2E). The intravesical administration
of SB505124 (5 µM) alone did not have a significant (p = 0.6506) treatment effect on
mean nerve firing (76.8 ± 17.7 to 63.9 ± 13.6 imp/sec, n=4) from 0-25 mmHg (Figure
2A, Figure 2B). Furthermore, SB505124 did not have a significant (p = 0.0782) effect on
distention-evoked urothelial ATP release at 25 mmHg (4.8 ± 1.7 to 7.2 ± 2.5 pmol/ml,
n=4).
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TGF-β1 stimulated ATP release from the urothelium through vesicular exocytosis
mechanisms to mediate bladder afferent nerve hyperexcitability.
Vesicular ATP release. The continuous intravesical instillation of BFA (10 µM)
did not have a significant (p = 0.8960) treatment effect on mean bladder afferent nerve
firing (68.7 ± 12.6 to 58.7 ± 15.1 imp/sec, n=3) from 0-25 mmHg (Figure 3A, Figure
3B). Similarly, the intravesical co-administration of recombinant TGF-β1 (10 ng/ml) and
BFA (10 µM) did not have a significant (p = 0.5646) treatment effect on mean nerve
firing (68.7 ± 12.6 to 63.4 ± 21.4 imp/sec, n=3) from 0-25 mmHg (Figure 3C, Figure
3D). The intravesical co-administration of BFA also attenuated (p = 0.2155) TGF-β1
mediated distention-evoked urothelial ATP release at 25 mmHg (Figure 3E).
Pannexin-1 channel ATP release. The continuous intravesical instillation of
10Panx (50 µM) did not have a significant (p = 0.1340) treatment effect on mean bladder
afferent nerve firing (41.9 ± 1.8 to 42.8 ± 3.9 imp/sec, n=4) from 0-25 mmHg (Figure 4A,
Figure 4B). The intravesical co-administration of recombinant TGF-β1 (10 ng/ml) and
10Panx (50 µM), however, had a significant (p = 0.0213) treatment effect on mean nerve
frequency with nerve firing increased (41.9 ± 1.8 to 50.1 ± 3.4 imp/sec, n=4) by 19.4%
from 0-25 mmHg (Figure 4C, Figure 4D). More specifically, nerve discharge
significantly increased from 10-15 (p = 0.0014), 15-20 (p ≤ 0.0001) and 20-25 (p =
0.0008) mmHg (Figure 4D). Relative to TGF-β1 alone (1.67 fold, Figure 1B), TGF-β1
and 10Panx co-administration (1.18 fold, Figure 4D) significantly (p = 0.0397) decreased
the magnitude of change only from 20-25 mmHg. Distention-evoked urothelial ATP
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release at 25 mmHg was also significantly (p = 0.0465) increased with the intravesical
co-administration of TGF-β1 and 10Panx (Figure 4E).
Purinoceptor signaling. The continuous intravesical instillation of PPADS (300
µM) did not have a significant (p = 0.2339) treatment effect on mean bladder afferent
nerve firing (75.9 ± 25.1 to 64.0 ± 16.9 imp/sec, n=4) from 0-25 mmHg (Figure 5A,
Figure 5B). The intravesical co-administration of recombinant TGF-β1 (10 ng/ml) and
PPADS (300 µM) attenuated (p = 0.2941) afferent nerve hyperexcitability (75.9 ± 25.1 to
59.2 ± 11.9 imp/sec, n=4) from 0-25 mmHg (Figure 5C, Figure 5D). The intravesical coadministration of TGF-β1 and PPADS, however, significantly (p = 0.0403) increased
distention-evoked urothelial ATP release at 25 mmHg (Figure 5E).
Bladder afferent nerve hyperexcitability and urothelial ATP release with CYP-induced
cystitis is decreased with TGF-β inhibition.
CYP-induced cystitis had a significant (p ≤ 0.0001) treatment effect on mean
bladder afferent nerve frequency (imp/sec) and nerve firing increased (62.2 ± 7.2 to 179.8
± 20.9 imp/sec, n=4-19) by 188.9% from 0-25 mmHg relative to control (Figure 6A,
Figure 6B). Nerve discharge significantly increased from 5-10 (p ≤ 0.0001), 10-15 (p ≤
0.0001), 15-20 (p ≤ 0.0001) and 20-25 (p ≤ 0.0001) mmHg (Figure 6B). The continuous
intravesical instillation of SB505124 (5 µM) significantly (p = 0.0028) decreased mean
nerve frequency with CYP-induced cystitis (Figure 6C, Figure 6D). Mean nerve firing
decreased (179.8 ± 20.9 to 103.6 ± 6.0 imp/sec, n=4) by 40.6% from 0-25 mmHg with a
significant decrease in discharge from 5-10 (p = 0.0041), 10-15 (p = 0.006) and 15-20 (p
= 0.0197) mmHg following SB505124 instillation (Figure 6D). TβR-1 inhibition with
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SB505124 also significantly (p = 0.0190) decreased distention-evoked urothelial ATP
release at 25 mmHg following CYP-induced cystitis (Figure 6E). The vehicle wash out of
SB505124 increased nerve firing (103.6 ± 6.0 to 172.8 ± 21.9 imp/sec, n=4) and
urothelial ATP release (6.3 ± 2.9 to 17 ± 3.7 pmol/ml, n=4) back to baseline.
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Discussion
The present study revealed that purinergic signaling mechanisms underlie TGFβ mediated bladder afferent nerve excitability in both control and CYP-treated tissues.
We determined that TGF-β1 contributes to bladder afferent nerve hyperexcitability
through increased ATP release from the urothelium by vesicular exocytosis mechanisms.
We also demonstrated that blocking aberrant TGF-β signaling in cystitis with TβR-1
inhibition decreased bladder afferent nerve discharge and urothelial ATP release. These
studies delineate the sensory components of the urinary bladder that may underlie the
interface between the upregulation of inflammatory mediators and bladder dysfunction.
ATP release. The urothelium participates in the sensory processing of bladder
filling by releasing neuroactive factors, such as ATP (Wang et al., 2005; Birder &
Andersson, 2013). The altered release of ATP in many functional disorders of the urinary
bladder (Sun et al., 2001; Sun & Chai, 2006; Silva-Ramos et al., 2013) suggest purinergic
signaling may contribute to the pathophysiology of bladder dysfunction (Ruggieri, 2006).
We determined that a previously identified inflammatory mediator of cystitis, TGF-β1
(Gonzalez et al., 2013), was able to stimulate an increase in distention-evoked release of
ATP from the urothelium (Figure 1D). The release of ATP was specific to ligand/receptor
activation because the co-administration of TGF-β1 with a TβR-1 inhibitor, SB505124
(DaCosta Byfield et al., 2004), attenuated an elevation in extracellular ATP (Figure 2F).
Not surprisingly, TGF-β1 continued to stimulate distention-evoked ATP release from the
urothelium when P2 receptors were inhibited downstream of the release pathways with
the co-administration of PPADS (Figure 5F). Aberrant TGF-β activation that was
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previously observed with CYP-induced cystitis (Gonzalez et al., 2013) also contributed to
altered ATP release. In our studies with cystitis, the inhibition of aberrant TGF-β
signaling significantly reduced urothelial ATP release that recovered immediately with
vehicle washout (Figure 6F). These results suggest that TGF-β signaling may directly
contribute to the altered sensory processing of bladder filling by increasing ATP release
from the urothelium.
Urothelial cells release ATP through various mechanisms that include vesicular
exocytosis (Wang et al., 2005; Sui et al., 2014; McLatchie & Fry, 2015),
connexin/pannexin channels (Wang et al., 2005; Sui et al., 2014; Beckel et al., 2015;
McLatchie & Fry, 2015) and nucleoside transporters (Wang et al., 2005). Although each
mechanism may play a part in release, our studies focused on the pharmacological
manipulation of vesicular exocytosis and pannexin-1 channels due to the disputed role of
transporters in uroepithelial cells (Knight et al., 2002) and because TGF-β1
downregulates connexin hemichannels in the bladder (Neuhaus et al., 2009) suggesting
an alternative mechanism for increased ATP release. We intravesically instilled the
general secretory inhibitor, BFA, for vesicular release inhibition. BFA has previously
been shown to decrease mechanical- and stretch-evoked ATP release from the urothelium
(Wang et al., 2005; Sui et al., 2014; McLatchie & Fry, 2015). We also intravesically
instilled the inhibitory peptide, 10Panx, to block pannexin-1 channels. These channels
have recently been implicated in distention-evoked ATP release from the urothelium with
pharmacological or genetic manipulation (Negoro et al., 2014; Timoteo et al., 2014;
Beckel et al., 2015).
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Our studies with BFA or 10Panx co-administration with TGF-β1 demonstrated
that the majority of urothelial ATP release stimulated by TGF-β1 occurred through
vesicular exocytosis (Figure 3F, Figure 4F). While these results suggest a vesicular
secretory mechanism, the effects of BFA may also generalize to inhibit the transport of
cell surface proteins, like hemichannels, to attenuate release (Wang et al., 2005). Further
studies are needed to separate the effects of vesicle release and hemichannel inhibition,
however, given that TGF-β1 downregulates connexin hemichannels and pannexin-1
channels had a minimal role in TGF-β1 stimulated ATP release, it is likely that the effects
we observed are due to vesicular secretory release. Future studies in our lab will aim to
resolve the intracellular signaling cascade that may promote ATP release through these
mechanisms.
Bladder afferent nerve excitability. Purinergic signaling is recognized to
directly influence the afferent limb of the micturition reflex and bladder function. The
intravesical instillation of ATP enhanced spinal bladder neuron excitability (Munoz et al.,
2011) and increased bladder activity (Pandita & Andersson, 2002). Non-voiding bladder
contractions and voiding frequency, on the other hand, were decreased when ATP release
was attenuated with the inhibition of vesicular (Smith et al., 2005) or pannexin-1 channel
(Timoteo et al., 2014; Beckel et al., 2015) release mechanisms, respectively. Our studies
determined that the decrease in distention-evoked ATP release from the urothelium
through vesicular exocytosis or pannexin-1 channels did not significantly contribute to
mechanosensitive afferent nerve discharge. This suggests that the decrease in bladder
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function previously observed occurred through an as yet unknown mechanism that is
independent of afferent nerve excitability.
Extracellular ATP may contribute to bladder sensory processing through the
activation of purinergic receptors on various cell types within the bladder wall including
afferent nerve terminals. The activation of P2 receptors with intravesical alpha,betamethylene ATP or ATP increased bladder afferent nerve discharge (Yu & de Groat,
2008) that was mediated mainly through capsaicin-insensitive C fibers (Aizawa et al.,
2011). Following intravesical P2 receptor inhibition, bladder activity decreased (Beckel
et al., 2015) and afferent nerve discharge decreased (Namasivayam et al., 1999;
Vlaskovska et al., 2001) or remained the same (Yu & de Groat, 2008). Our current study
determined that intravesical PPADS decreased nerve frequency by 15.7% but did not
have a significant effect on afferent nerve discharge. Taken together, these conflicting
studies indicate that purinergic receptors may only be activated on C fibers during
pathological conditions of elevated extracellular ATP to contribute to the sensation of
bladder filling.
The aforementioned contributions of purinergic signaling to bladder sensory
transduction and function suggests that an insult, like inflammation, that alters ATP
release may also affect nerve excitability. Given the functional overexpression of TGF-β
in CYP-induced cystitis (Tyagi et al., 2009; Zhang & Qiao, 2012; Gonzalez et al., 2013)
and its ability to stimulate ATP release in our current studies, we sought to determine if
TGF-β1 also contributes to bladder afferent nerve hyperexcitability. The intravesical
instillation of TGF-β1 increased nerve excitability by 41.8% and its significant effects on
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nerve discharge were observed nearly throughout the entirety of the filling phase (Figure
1D). Nerve hyperexcitability was dependent on receptor activation and subsequent
release of ATP because the intravesical co-administration of TGF-β1 and a TβR-1
inhibitor, SB505124, attenuated ATP release and bladder afferent nerve discharge (Figure
2F).
In addition to the necessity of TGF-β receptor activation, we also demonstrated
that TGF-β1 stimulates ATP release through vesicular exocytosis to increase afferent
nerve firing. Decreasing the release of ATP from the urothelium with BFA coadministration attenuated TGF-β1 mediated afferent nerve hyperexcitability (Figure 3F).
The co-administration of TGF-β1 and 10Panx, however, significantly increased
distention-evoked ATP release and afferent nerve discharge suggesting minimal
contribution from pannexin-1 channels in this response (Figure 4F). The elevated
extracellular ATP stimulated by TGF-β1 is likely activating nerve terminals within the
bladder wall to increase excitability. We demonstrated that the intravesical coadministration of PPADS attenuated TGF-β1 mediated bladder afferent nerve
hyperexcitability suggesting a role for these purinergic receptors in suburothelial afferent
nerve firing (Figure 5F). Intravesical PPADS may also be working at the level of the
urothelium to inhibit further basolateral release of ATP or other mediators that enhance
excitability (Figure 5F) (Sun & Chai, 2006). Future studies are still needed to determine
the basolateral release of ATP in this model because the concentrations of ATP that we
quantified in the lumen likely underrepresents basolateral release onto sensory fibers due
to volume differences in the interstitium, tissue-associated
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ectonucleotidases/exonucleotidases (Wang et al., 2005) and cell-type specific ATP
release (Cheng et al., 2011; McLatchie & Fry, 2015). Currently, the direct activation of
purinergic receptors within the wall of an intact urinary bladder remains difficult to
investigate without disrupting normal bladder physiology.
TGF-β is increased in the urine (Tyagi et al., 2009), urothelium (Tyagi et al.,
2009; Gonzalez et al., 2013) and detrusor smooth muscle (Zhang & Qiao, 2012; Gonzalez
et al., 2013) following CYP-induced cystitis. CYP-induced cystitis is characterized by
voiding dysfunction and TGF-β is considered to contribute, in part, to the development of
these lower urinary tract symptoms because TβR-1 inhibition decreased voiding
frequency and increased bladder capacity (Gonzalez et al., 2013). We confirmed that
bladder afferent nerve hyperexcitability is increased in CYP-induced cystitis (Yu & de
Groat, 2008) and demonstrated a functional role for aberrant TGF-β signaling in this
response (Figure 6F). Our current studies determined that TβR-1 inhibition may improve
voiding dysfunction by decreasing ATP release from the urothelium and decreasing nerve
firing by 40.6%. These effects were specific to aberrant TGF-β activation because vehicle
washout increased ATP release and recovered nerve hyperexcitability to baseline. The
decreased release of ATP with TβR-1 inhibition may normalize purinergic signaling and
work comparably to intravesical P2X inhibition that has been previously reported to
decrease afferent nerve excitability in CYP-induced cystitis (Yu & de Groat, 2008). It
should also be noted that while TβR-1 inhibition significantly decreased distentionevoked ATP release and afferent nerve excitability, nerve frequency did not reach control
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activity suggesting that other neuroactive mediators may be influencing
mechanosensitive nerve discharge with cystitis.
Conclusion. In summary, our studies highlight the role of purinergic signaling
in TGF-β mediated bladder afferent nerve hyperexcitability. The apparent synergy
between a component of the bladder inflammatory milieu and intrinsic signaling
mechanisms discussed here will contribute to the understanding of the pathophysiology
of bladder injury or disease. The distinct interactions of multiple signal transducers
underscore the challenges for single target therapies and support the development of
combinatory therapeutics for bladder dysfunction.
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Figure 1: TGF-β1 increased distention-evoked bladder afferent nerve discharge and ATP release
(A) Representative traces of vehicle (gray) and recombinant TGF-β1 (10 ng/ml, black) instillation from the
same preparation. (B) TGF-β1 significantly increased mean bladder afferent nerve frequency (imp/sec) by
41.8% relative to control with significant nerve discharge increase from 5-10, 10-15, 15-20 and 20-25
mmHg. (C) TGF-β1 significantly increased distention-evoked ATP release at 25 mmHg. (D) Proposed
mechanisms of purinergic signaling with TβR activation. n=4-8; values are mean ± SEM; *p ≤ 0.05, ***p ≤
0.001, ****p ≤ 0.0001 by two-way repeated measures ANOVA followed by Sidak’s multiple comparisons
test. #p ≤ 0.01 by Student’s paired t test.
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Figure 2: Distention-evoked bladder afferent nerve discharge and ATP release are unchanged with
the co-administration of TGF-β1 and SB505124
(A) Representative traces of vehicle (gray) and SB505124 (5 μM, black) instillation from the same
preparation. (B) SB505124 did not have a significant treatment effect on mean bladder afferent nerve
frequency (imp/sec) relative to control. (C) Representative traces of vehicle (gray) and recombinant TGFβ1 (10 ng/ml, black) and SB505124 (5 μM, black) co-instillation from the same preparation. Concurrent
instillation of TGF-β1 and SB505124 attenuated distention-evoked bladder afferent nerve hyperexcitability
(D) and ATP release (E) mediated by TGF-β1. (F) Proposed mechanisms of purinergic signaling with TβR
inhibition. n=4-7; values are mean ± SEM.
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Figure 3: Distention-evoked bladder afferent nerve discharge and ATP release are unchanged with
the co-administration of TGF-β1 and BFA
(A) Representative traces of vehicle (gray) and BFA (10 μM, black) instillation from the same preparation.
(B) BFA did not have a significant treatment effect on mean bladder afferent nerve frequency (imp/sec)
relative to control. (C) Representative traces of vehicle (gray) and recombinant TGF-β1 (10 ng/ml, black)
and BFA (10 μM, black) co-instillation from the same preparation. Concurrent instillation of TGF-β1 and
BFA attenuated distention-evoked bladder afferent nerve hyperexcitability (D) and ATP release (E)
mediated by TGF-β1. (F) Proposed mechanisms of purinergic signaling with TβR activation and BFA. n=38; values are mean ± SEM.
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Figure 4: TGF-β1 and 10Panx co-administration increased distention-evoked bladder afferent nerve
discharge and ATP release
(A) Representative traces of vehicle (gray) and 10Panx (50 μM, black) instillation from the same
preparation. (B) 10Panx did not have a significant treatment effect on mean bladder afferent nerve
frequency (imp/sec) relative to control. (C) Representative traces of vehicle (gray) and recombinant TGFβ1 (10 ng/ml, black) and 10Panx (50 μM, black) co-instillation from the same preparation. (D) Concurrent
instillation of TGF-β1 and 10Panx significantly increased mean bladder afferent nerve frequency (imp/sec)
by 19.4% relative to control with significant nerve discharge increase from 10-15, 15-20 and 20-25 mmHg.
(E) TGF-β1 significantly increased distention-evoked ATP release at 25 mmHg when co-administered with
10Panx. (F) Proposed mechanisms of purinergic signaling with TβR activation and 10Panx. n=4-7; values
are mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, **** p ≤ 0.0001 by two-way repeated measures
ANOVA followed by Sidak’s multiple comparisons test. #p ≤ 0.05 by Student’s paired t test.
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Figure 5: Distention-evoked bladder afferent nerve discharge is unchanged but ATP release is
increased with the co-administration of TGF-β1 and PPADS
(A) Representative traces of vehicle (gray) and PPADS (300 μM, black) instillation from the same
preparation. (B) PPADS did not have a significant treatment effect on mean bladder afferent nerve
frequency (imp/sec) relative to control. (C) Representative traces of vehicle (gray) and recombinant TGFβ1 (10 ng/ml, black) and PPADS (300 μM, black) co-instillation from the same preparation. (D)
Concurrent instillation of TGF-β1 and PPADS attenuated distention-evoked bladder afferent nerve
hyperexcitability mediated by TGF-β1. (E) TGF-β1 significantly increased distention-evoked ATP release
at 25 mmHg when co-administered with PPADS. (F) Proposed mechanisms of purinergic signaling with
TβR activation and PPADS. n=4-5; values are mean ± SEM. #p ≤ 0.05 by Student’s paired t test.
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Figure 6: SB505124 decreased distention-evoked bladder afferent nerve hyperexcitability and ATP
release with CYP-induced cystitis
(A) Representative traces of CYP-induced cystitis (gray) and control (black) instillation. (B) CYP-induced
cystitis significantly increased mean bladder afferent nerve frequency (imp/sec) by 188.9% relative to
control with significant nerve discharge increase from 5-10, 10-15, 15-20 and 20-25 mmHg. (C)
Representative traces of CYP-induced cystitis (gray) and SB505124 (5 μM, black) instillation from the
same CYP preparation. (D) SB505124 significantly decreased mean bladder afferent nerve frequency
(imp/sec) by 40.6% relative to CYP with significant nerve discharge decrease from 5-10, 10-15 and 15-20
mmHg. (E) SB505124 significantly decreased distention-evoked ATP release with CYP-induced cystitis.
(F) Proposed mechanisms of purinergic signaling with TβR inhibition and CYP-induced cystitis. n=4-19;
values are mean ± SEM; *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001 by two-way repeated measures ANOVA
followed by Sidak’s multiple comparisons test. #p ≤ 0.05 by Student’s paired t test.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
4.1. Summary
BPS/IC is a chronic pain syndrome characterized by lower urinary tract
symptoms and pain or discomfort thought to be bladder related. BPS/IC impacts the
quality of life of the 3.3-7.9 million women (>18 years old) in the United States who
exhibit symptoms and burdens the economy with significant financial ramifications
(Berry et al., 2011). Currently, the etiology of altered visceral sensation that accompanies
BPS/IC is not known. We propose that neurochemical alterations in the urinary bladder
contribute to peripheral afferent activation and sensitization to underlie bladder
dysfunction (Figure 1). The studies in this dissertation identified and described one
potential inflammatory mediator, TGF-β, that may be used as a diagnostic marker and/or
target in the lower urinary tract to improve function with urinary bladder inflammation.
The following sections will discuss its clinical implications and the potential to expand
this work.
4.2. Summary and Future Directions: ATP Release
The sensory processing of bladder filling is proposed to involve the release of
ATP from the urothelium and the activation of P2X3 and P2X2/3 receptors on afferent
nerve terminals (Kaan et al., 2010; Rong, Spyer, & Burnstock, 2002). Any perturbation
that increases ATP release may therefore alter nerve excitability and underlie the
development of micturition reflex dysfunction. We first demonstrated that aberrant TGFβ signaling contributed, in part, to altered ATP release following CYP-induced cystitis
(Figure 1). We next determined that TGF-β1 can directly stimulate the release of ATP
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from the urothelium and that the effect was specific to receptor activation because the coadministration with a TβR-1 inhibitor attenuated ATP release (Figure 1). We also
determined that vesicular exocytosis mechanisms contributed more than pannexin-1
channels to ATP release mediated by TGF-β1 (Figure 1).
Our current studies were limited to measuring the luminal content of ATP due to
methodological limitations. To confirm that TGF-β1 also stimulates basolateral ATP
release that may then directly activate bladder afferent nerve terminals, we would use
urothelial sheets in an Ussing chamber. The Ussing chamber would allow us to separate
the mucosal and serosal compartments of the urothelium to measure ATP release into
each chamber. Similar to other studies, we would expect that the luminal application of
ATP would increase serosal ATP release (Sun & Chai, 2006). We would also expect the
luminal application of TGF-β1 to increase serosal ATP release. While the addition of
these experiments would strengthen our overall conclusions, the functional changes we
observed in bladder-pelvic nerve preparations suggest we are altering the basolateral
release of neuroactive transmitters.
A mechanism that is not yet known in our model is the intracellular signaling
cascade that TGF-β activates to stimulate ATP release. ATP release can be regulated, in
part, by increases in intracellular calcium (McLatchie & Fry, 2015) and PKA second
messenger cascades (Wang et al., 2005). Previous studies have reported that TGF-β can
induce a sustained increase in intracellular calcium through type III IP3 receptors
(McGowan et al., 2002). TGF-β has also been demonstrated to activate PKA, a response
that was independent to an increase in cAMP (Zhang et al., 2004). We can examine these
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mechanisms through various experiments that include chelating and reducing
intracellular calcium with BAPTA-AM, inhibiting calcium release from IP3-dependent
stores in the ER with 2-aminoethoxydiphenylborate (APB) (Ma, Venkatachalam, Parys,
& Gill, 2002) and blocking PKA with cell permeable inhibitors H89 or PKI (5-24). These
experiments would give us further insight into the intracellular mechanisms that underlie
TGF-β mediated ATP release and may provide another target to improve voiding
dysfunction.

Figure 1: Schematic of TGF-β and purinergic signaling within the sensory components of the urinary
bladder
TβR activation evokes ATP release from urothelial cells through vesicular exocytosis mechanisms. These
extracellular nucleotides may activate P2X/P2Y receptors on underlying cells, including afferent nerve
terminals, to increase excitability. The resultant afferent nerve hyperexcitability may alter the sensory
processing of bladder filling and contribute to increased voiding frequency. Abbreviations: ATP, adenosine
triphosphate; BFA, brefeldin A; Ca++, calcium; Det, detrusor; G, g-protein coupled receptor; ICC,
interstitial cells of Cajal; Na+, sodium; P2, purinergic receptor; Panx, pannexin; PPADS,
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid; TβR, transforming growth factor-beta receptor.
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4.3. Summary and Future Directions: Afferent Limb of the Micturition Reflex
Our studies demonstrated a role for TGF-β signaling in the afferent limb of the
micturition reflex because intravesical TGF-β1 instillation increased bladder afferent
nerve frequency and intravesical TβR-1 inhibition with SB505124 decreased bladder
afferent nerve excitability and decreased voiding frequency following CYP-induced
cystitis. TGF-β may alter nerve excitability indirectly by enhancing the release of
neuroactive molecules from the urothelium or directly by activating receptors on nerve
terminals. Our studies suggest that the intravesical treatment instillation was likely having
an indirect effect on nerves through the urothelium and purinergic signaling (Figure 1). In
addition to TGF-β1 stimulating ATP release, TGF-β1 affected nerve excitability in
control tissues with an intact barrier suggesting a role for urothelial sensory processing
(Figure 1). These experiments, however, cannot discount the possible direct effect on
nerve terminals that TGF-β1 may be having in CYP-induced cystitis.
Future studies can use whole-cell patch-clamp recording techniques to examine
the direct role of TGF-β1 on primary afferent cell bodies (dorsal root ganglia) innervating
the urinary bladder. Neurons projecting from the urinary bladder would first be labeled
with fast blue and then selected for intracellular recordings. We would expect TGF-β1 to
contribute to peripheral sensitization by increasing spontaneous and evoked action
potentials as previously described (Zhu et al., 2012). Several mechanisms have been
proposed to underlie this TGF-β mediated excitability. The phosphorylation of TRPV1
by TGF-β mediated upregulation of Cdk5 has previously been shown to induce
hyperexcitability in sensory neurons (Utreras et al., 2012). Similarly, TGF-β has been
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previously shown to modulate KCNA4 transcript expression in sensory neurons resulting
in a decrease of IA currents and hyperexcitability (Zhu et al., 2012). Future experiments
may look at these mechanisms within urinary bladder sensory neurons to determine if
they have a role in CYP-induced cystitis.
4.4. Future Directions: Detrusor Smooth Muscle
TGF-β can affect smooth muscle cell contractility by altering cytoskeletal (Hu et
al., 2006) and contractile protein expression (Grainger, Metcalfe, Grace, & Mosedale,
1998). TGF-β1 has also been demonstrated to increase contractility of primary human
bladder smooth muscle cells through the effector JunB (Ramachandran et al., 2013).
Since TGF-β1 is increased in the detrusor smooth muscle with intermediate (48 h) CYPinduced cystitis, we would expect to see similar functional changes in contractility. We
would determine the contribution of aberrant TGF-β signaling to detrusor contractility
with CYP-induced cystitis using detrusor smooth muscle strips suspended from force
transducers. We would first confirm previous studies that showed an increase in
spontaneous contractions with CYP-induced cystitis (Okinami et al., 2014). We would
next superfuse the TβR-1 inhibitor, SB505124, through the bath solution and expect to
observe an inhibition of TGF-β1-induced contractility.
The isolation of smooth muscle strips may not completely reflect intravesical
pressure changes in open outlet cystometry because of not having an intact micturition
reflex. As a result, these studies must be interpreted cautiously and in the context of the in
vivo cystometrogram measurements. Our cystometry data demonstrated no changes in
intravesical pressure (filling, threshold and peak) following CYP-induced and the
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intravesical instillation of SB505124. This suggests that the detrusor smooth muscle was
not involved in the decreased voiding frequency and increased bladder capacity, void
volume and longer intercontraction intervals we observed. An alternative explanation is
that while TβR-1 inhibition may alter contractility, SB505124 is simply not reaching the
detrusor smooth muscle with intravesical instillation. Future studies can circumvent this
problem and determine its involvement by administering SB505124 intravenously so that
it can more readily access the smooth muscle.
4.5. Future Directions: Somatic Hypersensitivity
BPS/IC is characterized by pain perceived to emanate from the urinary bladder.
In modeling this syndrome, CYP-induced cystitis has been demonstrated to increase
hindpaw and pelvic somatic sensitivity (Arms, Girard, Malley, & Vizzard, 2013). Given
the role of TGF-β1 in central and peripheral sensitization (Lantero, Tramullas, Diaz, &
Hurle, 2012), we would expect to see a contribution of TGF-β1 to somatic
hypersensitivity. Von Frey monofilaments can be used to determine referred pelvic and
hindpaw sensitivity in CYP-treated animals with TβR-1 inhibition. The animals would be
placed in a plexiglass chamber with a wire mesh floor and then tested for tactile allodynia
and secondary hyperalgesia using these calibrated filaments to the abdomen and hindpaw.
We would expect the intravesical instillation of SB505124 to decrease tactile allodynia
and secondary hyperalgesia as evidenced by decreased withdrawal frequencies relative to
baseline measurements in CYP-treated animals. The addition of these experiments would
determine the role(s) of TGF-β1 in the development of somatic pain symptoms with
cystitis.
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4.6. Clinical Implications
The neural circuitry underlying the micturition reflex is complex and is often
compromised with neural injury, disease or inflammatory conditions. Our studies utilized
the preclinical CYP-induced cystitis model to characterize the neurochemical plasticity in
the sensory components of the urinary bladder. We demonstrated elevated levels of TGFβ ligands and their cognate receptors following cystitis and determined their functional
expression in the afferent limb of the micturition reflex. Given the diversity of bladder
syndromes, it remains to be determined if certain inflammatory mediators and
downstream signaling pathways are unique to specific conditions. Nevertheless, the
inhibition of cytokine/receptor signaling may represent a therapeutic avenue for
inflammation-associated bladder dysfunction.
The presence of inflammatory molecules, like TGF-β, in the urine or urothelium
may be a useful biomarker for monitoring inflammation or tracking responses to
treatment in bladder syndromes. At this moment, the diagnostic criteria of BPS/IC are
dependent on cystoscopy and symptom-based lower urinary tract dysfunction (Kuo,
2014). Potential markers, such as elevated urinary proteins (Erickson et al., 2002) and
serum cytokines (Jiang, Peng, Liu, & Kuo, 2013), have been suggested to permit an
earlier treatment intervention to control or slow disease progression. Currently, however,
these markers are likely not specific enough to differentially diagnose bladder syndromes
(BPS/IC, OAB, etc.) (Kuo, 2014). While TGF-β may not be a diagnostic marker for
BPS/IC, it does appear to offer an alternative method to track the progression of
inflammation and tissue repair due to its temporal regulation in CYP-induced cystitis.
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Future longitudinal studies must determine if inflammatory mediators, like TGF-β,
follow this time course in clinical populations. The continued characterization of
neurochemical alterations in bladder syndromes may improve patient outcome by
offering more selective treatment options that are dependent on the profile of markers
expressed.
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Abstract
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic bladder disorder
characterized by pressure, discomfort, and pain perceived to be related to the urinary
bladder, with at least one urinary symptom. We hypothesized that cyclophosphamide
(CYP)-induced cystitis results in oxidative stress and contributes to urinary bladder
dysfunction. We determined: (1) the expression of oxidative stress markers (3nitrotyrosine (3-NT), reactive oxygen species (ROS)/reactive nitrogen species (RNS),
inflammatory modulators, neuropeptides (calcitonin gene-related peptide (CGRP);
substance P (Sub P), and adenosine triphosphate (ATP) that contribute to the
inflammatory process in the urinary tract and (2) the functional role of oxidative stress in
urinary bladder dysfunction with an antioxidant, Tempol (1 mM in drinking water)
combined with conscious cystometry. In CYP-treated (4 hr of 48 hr; 150 mg/kg, i.p.) rats,
ROS/RNS and 3-NT significantly (p ≤ 0.01) increased in urinary bladder. CYP-treatment
increased ATP, Sub P and CGRP expression in the urinary bladder and cystometric fluid.
In CYP-treated rats, Tempol significantly (p ≤ 0.01) increased bladder capacity, and
reduced voiding frequency compared to CYP-treated rats without Tempol. Tempol
significantly (p ≤ 0.01) reduced ATP expression, 3-NT and ROS/RNS expression in the
urinary tract of CYP-treated rats. These studies demonstrate that reducing oxidative
stress in CYP-induced cystitis improves urinary bladder function and reduces markers of
oxidative stress and inflammation.
Keywords: reactive oxygen species, reactive nitrogen species, 3-nitrotyrosine, ATP,
neuropeptides, cystometry
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Introduction
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic syndrome
characterized by pressure, discomfort, and pain thought to arise from the urinary bladder,
with at least one urinary symptom [1, 2]. While the underlying etiology of BPS/IC is not
known, the majority of biopsies from BPS/IC patients reveal inflammation [3]. Mediators
of inflammation, including cytokines, chemokines, growth factors and neuropeptides,
have been shown to contribute to urinary bladder dysfunction and somatic sensitivity in
animal models of cystitis and in the clinical syndrome of BPS/IC [3, 4]. In addition,
reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated by
inflammation result in oxidative stress and may contribute to urinary bladder dysfunction
[5, 6]. The role(s) oxidants may have in inducing inflammation has been extensively
studied in diverse experimental models [7]. Although it is widely accepted that ROS/RNS
are fundamentally involved, antioxidant therapy as a valid means of arresting
inflammation remains largely unresolved especially in the context of urinary bladder
inflammation.
Accompanying oxidative stress and inflammatory mediator upregulation, the
urothelium may also respond to cystitis by increasing the secretion of neuroactive factors,
such as ATP, that signal to the underlying nerve plexus [8]. Altered release of these
neuromodulatory compounds has been suggested to contribute to increased sensory
transduction and result in urinary bladder dysfunction [4, 8]. In BPS/IC, for example,
distention-evoked release of ATP was increased in tissue biopsies that may have resulted
in the elevated urinary ATP observed in patients with BPS/IC [9]. Similarly, numerous
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animal models of cystitis have demonstrated increased distention-evoked release of ATP
from the urothelium [10, 11]. Further, purinergic receptor activation has been associated
with increased cellular production and release of multiple inflammatory mediators,
including superoxide anion, nitric oxide and other ROS [12]. Purinergic receptor
activation induces ROS generation in numerous cell types resulting in a variety of
downstream effects including, transcription factor activation [13], pro-inflammatory
cytokine release [14, 15] and cell death [16].
Using a rat model of urinary bladder inflammation induced by
cyclophosphamide (CYP) [3, 4, 17, 18], we determined: (1) the expression of oxidative
stress markers (3-nitrotyrosine (3-NT), ROS/RNS) and other modulators of
inflammation, the neuropeptides calcitonin gene-related peptide (CGRP) and substance P
(Sub P) in the urinary tract; (2) the contribution of ROS/RNS to ATP expression in the
urinary bladder and urine with an antioxidant and superoxide dismutase mimetic, Tempol
(1 mM in drinking water); and (3) the role of ROS/RNS in urinary bladder function with
Tempol combined with open outlet, conscious and continuous intravesical infusion [19] .
Although the etiology of BPS/IC is unknown, previous studies [3, 4, 17, 18] have
demonstrated that the rat CYP model of urinary bladder inflammation is a reliable and
reproducible model with face validity (e.g., increased voiding frequency and referred
somatic sensitivity) to BPS/IC. Previous studies have demonstrated roles for
neuropeptides, including CGRP and Sub P, in CYP-induced bladder dysfunction [39, 57]
and the current studies have continued to focus on these two neuropeptides, abundantly
expressed in bladder sensory pathways.
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Materials and Methods
Animals
Adult female, Wistar rats (200-225 g; Charles River, St. Constant, Canada) were
used for this study. Rats were housed two per cage and maintained in standard laboratory
conditions with free access to food and water. The University of Vermont Institutional
Animal Care and Use Committee approved all animal use procedures (protocol 08-085).
Animal experimentation was carried out in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals. All efforts were made to
minimize the potential for animal pain, stress or distress.
Induction of cyclophosphamide (CYP)-induced cystitis
Rats were anesthetized under isoflurane (2%) and acute cystitis was induced
with a single injection of CYP (150 mg/kg, i.p.) and used in studies at various time points
(4 hours (hr) or 48 hr) after treatment [20-22]. Control rats received volume-matched
injections of saline (0.9%; i.p.) or no treatment and no difference among the control
groups was observed. All injections were performed under isoflurane (2%) anesthesia.
The CYP model of bladder inflammation produces an increase in voiding frequency with
small micturition volumes and is associated with inflammatory cell infiltrates in the
urinary bladder including mast cells, macrophages and neutrophils [23, 24]. Rats were
euthanized using isoflurane (5%) and a thoracotomy.
For cystometry in conscious rats, an unrestrained animal was placed in a
Plexiglas cage with a wire bottom. Before the start of the recording, the bladder was
emptied and the catheter was connected via a T-tube to a pressure transducer (Grass
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Model PT300, West Warwick, RI) and microinjection pump (Harvard Apparatus 22,
South Natick, MA). A Small Animal Cystometry Lab Station (MED Associates, St.
Albans, VT) was used for urodynamic measurements [19, 28]. Saline solution was
infused at room temperature into the bladder at a rate of 10 ml/h to elicit repetitive
bladder contractions. At least six reproducible micturition cycles were recorded after the
initial stabilization period of 25–30 min [19, 28]. The following cystometric parameters
were recorded in each animal: baseline pressure (BP; pressure at the beginning of the
bladder filling), threshold pressure (TP; bladder pressure immediately prior to
micturition), peak micturition pressure (MP), intercontraction interval (ICI; time between
micturition events), bladder capacity (BC), void volume (VV), presence and amplitude of
non-voiding bladder contractions (NVCs) [19, 28]. NVCs were defined as rhythmic
intravesical pressure increases 7 cm H20 above baseline, during the filling phase, without
the release of fluid from the urethra. Bladder capacity (BC) was measured as the volume
of saline infused into the bladder at the time when micturition commenced [35]. In these
rats, residual volume was less than 10 μl; therefore, VV and BC were similar. After the
initial stabilization period, cystometric fluid expelled during micturition events was
collected and frozen on dry ice and stored at -80 ˚C for future use in the assays described
above. At the conclusion of the experiment, the rat was euthanized (5% isoflurane plus
thoracotomy), the urinary bladder was harvested and used in the assays described above.
Split bladder preparation and assessment of potential contamination of bladder layers
The urothelium + suburothelium was dissected from the detrusor smooth muscle
using fine forceps under a dissecting microscope as previously described [20, 21]. To
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confirm the specificity of our split bladder preparations, urothelium + suburothelium and
detrusor samples were examined for the presence of α-smooth muscle actin (1:1000;
Abcam, Cambridge, MA) and uroplakin II (1:25; American Research Products, Belmont,
MA) by western blotting or reverse transcription PCR [20, 25]. In urothelium +
suburothelium layers, only uroplakin II was present (data not shown). Conversely, in
detrusor samples, only α-smooth muscle actin was present (data not shown). All
subsequent measurements of urinary bladder and cystometric fluid samples and conscious
cystometry in rat groups were performed in a blind manner.
Substance P (Sub P), calcitonin gene-related peptide (CGRP), 3-nitrotyrosine (3-NT) by
enzyme-linked immunosorbent assays (ELISAs)
Tissue processing and ELISAs were performed as described previously [18, 26].
Briefly, rats from control (n = 6 each) and all experimental groups (n = 6 each) were
deeply anesthetized (4% isoflurane), and a thoracotomy was performed. Individual rat
bladders were dissected, weighed, and placed in Tissue Protein Extraction Reagent (1 g
tissue/20 ml; Pierce Biotechnology, Woburn, MA) with Complete protease inhibitor
cocktail tablets (Roche Applied Science, Mannheim, Germany), and stored at −80 °C. On
the day of assay, individual bladders were disrupted with a Polytron homogenizer until
homogeneous and centrifuged (10,000 rpm for 10 min) [18, 26], and the supernatant was
used for total protein estimation and CGRP (Phoenix Pharmaceuticals, Inc. Burlingame,
CA), Sub P (Phoenix Pharmaceuticals) and 3-NT (Millipore Corporation, Bellerica, MA)
quantification. Total protein was determined by the Coomassie Plus Protein Assay
Reagent Kit (Pierce) [18, 26] and CGRP, Sub P and 3-NT were quantified using standard
186

96-well ELISA plates (Phoenix Pharmaceuticals; Millipore Corporation) according to the
manufacturer's recommendations. For determination of Sub P and CGRP content in
voided cystometric fluid, void volumes were collected following each micturition event
in control and CYP-treated groups with and without Tempol (only vehicle)
administration during conscious cystometry (see below). For Sub P, CGRP and 3-NT
measurements in voided cystometric fluid, 6–8 individual voids/animal were collected
and immediately frozen on dry ice. Data from multiple voids were averaged, and the
mean value was used for each animal.
ELISAs for CRGP, Sub P, 3-NT expression in urinary bladder and voided cystometric
fluid
The microtiter plates (Phoenix Pharmaceuticals; Millipore Corporation) were
coated with mouse anti-rat CGRP, anti-rat Sub P or anti-rabbit-NT antibody. Sample and
standard solutions were run in duplicate. Horseradish peroxidase (HRP)-streptavidin or
HRP-conjugated goat anti-rabbit IgG and LumiGLO was used to detect the antibody
complex. Tetramethylbenzidine or LumiGLO was the substrate, and the enzyme activity
or luminescence was measured. The CRGP standard provided with this protocol
generated a standard curve from 0 to 100 ng/ml (R2 = 0.998, P ≤ 0.0001) for bladder
samples [26]. The Sub P standard provided with this protocol generated a standard curve
from 0 to 25 ng/ml (R2 = 0.998, P ≤ 0.0001) for bladder samples [26]. The nitrated-BSA
standard provided with this protocol generated a standard curve from 1.5 to 100 µg/ml
(R2 = 0.997, P ≤ 0.0001) for bladder samples. The absorbance values of standards and
samples were corrected by subtraction of the background value (absorbance due to
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nonspecific binding) [18, 26]. No samples were diluted and all samples had absorbance
values that fell onto the linear portion of the standard curve. Curve fitting of standards
and evaluation of protein content of samples were performed using a least-squares fit.
Measurement of cellular oxidative stress
The levels of cellular oxidative stress were determined by a spectrofluorimetric
method, using the dichlorofluorescein DiOxyQ (DCFH-DiOxyQ) assay (OxiSelect In
Vitro ROS/RNS Assay Kit (Green Fluorescence; Cell Biolabs, Inc., San Diego, CA,
USA). The urinary bladder was removed from control (n = 6 each) and all experimental
groups (n = 6 each) and rapidly homogenized in 50 mM Tris–Cl, pH 7.4. The
homogenate was centrifuged at 2400g for 15 min at 4 °C and a low-speed supernatant
fraction was used for assays. To determine levels of cellular oxidative stress, the
supernatant from the urinary bladder homogenate was diluted (1:10) in 50 mM Tris–HCl
(pH 7.4) and incubated with 10 μl of 2′,7′-DCHF-DA (1 mM), at 37 °C for 30 min. The
DCHF-DA is enzymatically hydrolyzed by intracellular esterases to form nonfluorescent
DCFH, which is then rapidly oxidized to form highly fluorescent 2′,7′dichlorofluorescein (DCF) in the presence of cellular oxidative stress species. DCF
fluorescence intensity is proportional to the amount of cellular oxidative stress species
that is formed. The DCF fluorescence intensity emission was recorded at 520 nm (with
480 nm excitation) 30 min after the addition of DCHF-DA to the sample. The cellular
oxidative species levels were expressed as fluorescence arbitrary units (FAU).
Collection and measurement of urinary ATP
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Sample collections. For determination of ATP in urinary bladder, urinary bladder harvest
and subsequent processing was performed as described above for ELISAs. For
determination of ATP content in voided cystometric fluid, void volumes were collected
following each micturition event in animal groups (control, CYP-treated groups, with and
without Tempol) during conscious cystometry. For ATP measurements in voided
cystometric fluid, 6–8 individual voids/animal were collected and immediately frozen on
dry ice and stored at -80 ˚C until use. Undiluted cystometric fluid samples were
defrosted till 25°C, centrifuged at 3000g at room temperature for 20 seconds to remove
cellular debris and the supernatant was separated. Data from multiple voids were
averaged, and the mean value was used for each animal.
ATP determination. A mixture of luciferin-luciferase was added according to the
manufacturer instructions using the ATP Bioluminescence Assay Kit HS II (Adenosine
Triphosphate (ATP) Bioluminescent Assay Kit, Sigma-Aldrich, St. Louis, MO, USA) as
previously described [27]. ATP detection was evaluated using a multi-mode microplate
reader (Synergy HT, BioTek Instruments Inc., Vermont, USA) controlled with Gen5™
Data Analysis Software (BioTek). Sample bioluminescence was compared to that of
standard amounts of ATP used in the same concentration range; standard ATP samples
were prepared daily. All samples were run in duplicate. Cystometric void data were
obtained from at least three voids/animal from control (n = 6 each) and all experimental
groups (n = 6 each) and urinary bladder data were obtained from control (n = 6 each) and
all experimental groups (n = 6 each). Vehicle for Tempol did not affect the ATP
determinations. The ATP in cystometric fluid or ATP content in urinary bladder was
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calculated relative to the standard curve, and expressed as nmol per total protein or nmol
per ml of urine.
Conscious Cystometry and effects of Tempol, a superoxide dismutase (SOD) mimetic
Rats were anesthetized with isoflurane (3-4%), a lower midline abdominal
incision was made, and polyethylene tubing (PE-50, Clay Adams, Parsippany, New
Jersey) was inserted into the bladder dome and secured with a nylon purse-string sutures
(6-zero) [19, 28]. The end of the PE tubing was heat flared, but the catheter did not
extend into the bladder body or neck and it was not associated with inflammation or
altered cystometric function [19, 28]. The distal end of the tubing was sealed, tunneled
subcutaneously and externalized at the back of the neck out of reach of the animal [19,
28]. Abdominal and neck incisions were closed with nylon sutures (4-zero).
Postoperative analgesics were given and animals were maintained for 72 to 96 hours after
survival surgery to ensure recovery.
Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), a superoxide
dismutase (SOD) mimetic, is a stable nitroxyl antioxidant. Previous studies have
suggested that Tempol is protective in disorders involving ROS [29-32]. The effects of
Tempol on urinary bladder function in CYP-treated (4 hr and 48 hr; n = 6 each) rats and
control rats (n = 6 each) were assessed using conscious, open outlet, cystometry with
continuous instillation of intravesical saline [19, 28]. Tempol was prepared daily with
distilled water purified with a Millipore Milli-Q system and administered in the drinking
water (1 mM) that was provided to rats ad libitum; untreated rats received water ad
libitum. Covered bottles were used to minimize degradation by light. The addition of
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Tempol to the drinking water did not affect water consumption (data not shown). For
CYP-treated rat groups (4 hr, 48 hr), Tempol was provided for approximately two weeks
(13-15 days) while the intravesical tube was implanted on day 10, CYP or vehicle was
injected on day 13 and rats were used in experiments on day 13-15. Due to the daily
administration and route of delivery (oral) of the Tempol, these experiments were
performed in different groups of control and CYP-treated rats treated with vehicle or
Tempol. The concentration (1 mM) of Tempol and duration of treatment used in these
studies was based upon previous studies [33, 34].
Exclusion Criteria
Rats were removed from the study when adverse events occurred that included
20% reduction in body weight post-surgery, a significant postoperative event, lethargy,
pain, or distress not relieved by our IACUC-approved regimen of postoperative
analgesics or hematuria in control rodents [19, 28]. In the present study, no rats were
excluded from the study. In addition, behavioral movements such as grooming, standing,
walking, and defecation rendered bladder pressure recordings during these events
unusable.
Statistical Analyses
All values represent mean ± SEM. Cystometry data were compared using
repeated measures ANOVA, where each animal served as its own control. Animals,
processed and analyzed on the same day, were tested as a block in the ANOVA. When Fratios exceeded the critical value (p ≤ 0.05), the Newman-Keuls or Dunnett's post hoc
tests were used to compare group means. Data obtained from the ATP assays violated the
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assumptions of the ANOVA. Thus, these data were analyzed using a non-parametric
analysis, the Mann-Whitney Rank Sum test. When F ratios exceeded the critical value (p
≤ 0.05), the Newman-Keul's post-hoc test was used to compare the experimental means.
P ≤ 0.05 (two-tailed) values were considered statistically significant.
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Results
ROS/RNS Expression in Urinary Bladder with CYP-induced Cystitis and the Effects of
Tempol
We determined the levels of reactive oxygen species (ROS) and reactive
nitrogen species (RNS) in the urinary bladder following CYP treatment (4 hr, 48 hr) and
in the presence of the antioxidant, Tempol. 4 hr and 48 hr CYP-induced cystitis
significantly (p ≤ 0.01) increased the total free radical presence in the detrusor and
urothelium that was significantly reduced (p ≤ 0.01) by Tempol (1 mM) delivered in the
drinking water (Figure 1A). With both 4 hr and 48 hr CYP-induced cystitis, the increase
in total free radical presence was significantly (p ≤ 0.01) greater in the detrusor compared
to the urothelium (Figure 1A). Basal expression of total free radical presence in the
detrusor was significantly (p ≤ 0.01) greater in the detrusor compared to the urothelium
(Figure 1A).
3-Nitrotyrosine (3-NT) Expression in Urinary Bladder with CYP-induced Cystitis and the
Effects of Tempol
3-NT, a product of tyrosine nitration mediated by RNS such as peroxynitrite
anion and nitrogen dioxide, is considered a marker of NO-dependent, RNS-induced
nitrative stress [36]. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01)
increased 3-NT expression in the urinary bladder that was significantly reduced (p ≤
0.01) by Tempol (1 mM) delivered in the drinking water (Figure 1B). 3-NT expression
in the urinary bladder was significantly (p ≤ 0.01) greater following 4 hr CYP-induced
cystitis compared to 48 hr CYP-induced cystitis (Figure 1B).
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Substance P (Sub P) and Calcitonin Gene-Related Peptide (CGRP) Expression in
Urinary Bladder and Cystometric Fluid with CYP-induced Cystitis and the Effects of
Tempol
The neuropeptides, Sub P and CGRP, are known modulators of inflammation
and may contribute to the pathogenesis of many diseases including migraine, asthma, and
urinary bladder inflammation [4, 37-39]. 4 hr and 48 hr CYP-induced cystitis
significantly (p ≤ 0.01) increased Sub P and CGRP expression in the urinary bladder
(Figure 2A; Figure 3A) and cystometric fluid (Figure 2B; Figure 3B) that was
significantly reduced (p ≤ 0.01) by Tempol (1 mM) delivered in the drinking water
(Figure 2A, 2B; Figure 3A, 3B). Sub P expression in the urinary bladder was similar
following 4 hr and 48 hr CYP-induced cystitis in the urinary bladder and cystometric
fluid (Figure 2A, 2B). In contrast, 48 hr CYP-induced cystitis resulted in significantly (p
≤ 0.01) greater CGRP expression in the urinary bladder and cystometric fluid compared
to the 4 hr time point (Figure 3A, 3B).
Adenosine Triphosphate (ATP) Expression in Urinary Bladder and Cystometric Fluid
with CYP-induced Cystitis and the Effects of Tempol
Numerous studies have described a role(s) for ATP in urinary bladder
dysfunction, pain and altered ATP release mechanisms in animal models and clinical
studies of BPS/IC [8]. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01)
increased ATP expression in the urinary bladder and cystometric fluid that was
significantly reduced (p ≤ 0.01) by Tempol (1 mM) delivered in the drinking water
(Figure 4A, 4B). ATP expression in the urinary bladder was similar following 4 hr and
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48 hr CYP-induced cystitis (Figure 4A). In contrast, 4 hr CYP-induced cystitis resulted
in significantly (p ≤ 0.01) greater ATP expression in the cystometric fluid compared to
the 48 hr time point (Figure 4B).
Effect of an Antioxidant, Tempol, on Bladder Function
Conscious, open outlet cystometry with continuous intravesical infusion of
saline was performed in separate groups (n = 6 each) of control and CYP-treated (48 h)
rats with or without Tempol (vehicle only) in the drinking water to determine bladder
function (Figure 5; Figure 6; Figure 7; Figure 8).
Control (no CYP treatment).
Tempol (1 mM) treatment had no effects on ICI, BC, or VV in control rats (no
CYP treatment) compared with control rats (no CYP treatment) treated with vehicle
(Figure 5). There were no changes in BP, TP, or peak MP with Tempol treatment
compared to control rats (no CYP treatment) treated with vehicle (Figure 6). Residual
volume in control rats with or without Tempol (vehicle) treatment was minimal (≤ 10 μl).
CYP treatment.
As previously demonstrated [20-22], and confirmed here, CYP treatment (4 hr
and 48 hr) increased void frequency and decreased BC, ICI, and VV compared with
control rats (no CYP treatment) (Figure 5; Figure 6; Figure 7; Figure 8). Additionally, 48
hr CYP-induced cystitis significantly (p ≤ 0.01) increased BP and TP (Figure 6). Tempol
in the drinking water (1mM) of CYP-treated rats (4 hr and 48 hr) significantly (p ≤ 0.01)
increased the ICI (i.e., decreased voiding frequency) (Figure 5A; 2.0-2.9-fold), increased
BC (Figure 5C; 2.8-3.1-fold), and increased VV (Figure 5B; 2.9-5.4-fold) compared to
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rats treated with CYP (4 hr and 48 hr) receiving vehicle (Figure 7; Figure 8). Tempol
treatment of CYP-treated rats (4 hr and 48 hr) increased BC to 70% of control rats (no
CYP treatment) (Figure 5C; Figure 7; Figure 8). Effects of Tempol on bladder function in
CYP-treated rats persisted for at least 2 hr. Residual volume in CYP (4 hr and 48 hr)treated rats with or without Tempol treatment was minimal and similar to that observed in
control (no CYP treatment) (≤ 10 μl). CYP-treated rats (4 hr and 48 hr) treated with or
without Tempol (vehicle) exhibited no differences in BP, TP or peak MP (Figure 6A-C).
Tempol also significantly (p ≤ 0.01) reduced the number (2.4 ± 0.4/micturition cycle vs.
0.6 ± 0.2/micturition cycle) and amplitude (11.2 ± 1.3 cm H20 vs. 7.5 ± 0.5 cm H20) of
NVCs (increases in bladder pressure during the filling phase without the release of fluid)
in 4 hr CYP-treated rats (Figure 7). The effects of Tempol on NVCs in the 48 hr CYPtreated group were not determined due to the dramatically increased voiding frequency
that made the presence of NVCs difficult to determine.
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Discussion
The present studies demonstrate several novel findings with respect to the
induction and reduction of oxidative stress with the antioxidant, Tempol, following
cyclophosphamide (CYP)-induced cystitis. CYP-induced cystitis (4 hr and 48 hr)
increased ROS/RNS and 3-NT expression in the urinary bladder. In addition, CYPinduced cystitis increased expression of neuropeptides, CGRP and Sub P, in the urinary
bladder as well as cystometric fluid collected during conscious cystometry. CYP-induced
cystitis also increased ATP in the urinary bladder and cystometric fluid. Providing rats
with the antioxidant, Tempol, in the drinking water prior to and during the induction of
CYP-induced cystitis significantly reduced the expression of ROS/RNS, CGRP, Sub P
and ATP in urinary bladder and cystometric fluid. Further, Tempol decreased voiding
frequency, increased the intercontraction interval and bladder capacity without effects on
urinary bladder pressures (baseline, threshold, peak) in rats with CYP-induced cystitis.
Tempol did not alter bladder function in control (no CYP treatment) rats. These studies
demonstrate that CYP-induced cystitis is associated with oxidative stress in the urinary
tract and that use of the antioxidant, Tempol, reduces oxidative stress and improves
urinary bladder function.
Molecular oxygen reduction results in the production of several reactive
intermediates that must be actively scavenged [40]. Under conditions of inflammation,
there may be insufficient scavenging of reactive intermediates that can lead to oxidative
stress and damage to cellular structure and function. Recent studies suggest the
generation of these reactive intermediates contribute to the pathogenesis of urinary
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bladder dysfunction with CYP administration [41-43]. The contribution of oxidative
stress in bladder inflammation following CYP is further supported by the attenuation of
tissue damage following the administration of agents with antioxidant properties, like
taurine [41], flavonoid [42], beta-carotene and others [43]. Our studies using the CYP
model of urinary bladder inflammation at two time points (4 hr and 48 hr) confirm the
expression of reactive intermediates including ROS/RNS and 3-NT in the urinary
bladder. Expression of ROS/RNS following CYP-induced cystitis was significantly
greater in the detrusor smooth muscle compared to the urothelium but both tissues
exhibited increased ROS/RNS compared to control (no CYP treatment) urinary bladder.
3-NT expression has been previously demonstrated in lower urinary tract tissues
following injury or inflammation. Partial outlet obstruction in rabbit is associated with
increased NT in mucosa [44] that is correlated with progressive decrease in contractility
of detrusor smooth muscle [45]. Previous studies demonstrated iNOS and NT
immunoreactivity in the urothelium and inflammatory infiltrates in the lamina propria of
individuals with BPS/IC with a Hunner’s lesion [47]. Consistent with this clinical study,
the present study demonstrates increased 3-NT in the urinary bladder following CYPinduced cystitis (4 hr and 48 hr) in a rat model. The amino acid tyrosine is particularly
susceptible to nitration and the formation of 3-NT may represent a biomarker for the
generation of reactive nitrogen intermediates in vivo [47]. In addition to being a
biomarker, 3-NT could also have a detrimental impact on cell function and viability by
inhibiting protein phosphorylation by tyrosine kinases and interfering with the signal
transduction mechanism [48]. In addition, in vitro nitration of a specific tyrosine residue
198

inactivates manganese superoxide dismutase [49] that may lead to a greater concentration
of ROS/RNS perpetuating tissue damage and altered function.
As a major sensory component of the urinary bladder, the urothelium is able to
respond to various extracellular stimuli by releasing neuroactive factors like ATP,
acetylcholine and nitric oxide [8]. The sustained release of these factors, such as what
may occur with inflammation, may underlie the development of urinary bladder
dysfunction and lower urinary tract symptoms. The role of oxidative stress with ATP
release in epithelial cells, however, is not well defined. In endothelial cells, oxidative
stress has been demonstrated to mediate the direct release of ATP and inhibit the
catabolism of extracellular ATP [50, 51]. Further, purinergic receptor activation has been
associated with increased cellular production and release of multiple inflammatory
mediators, including superoxide anion, nitric oxide and other ROS. Purinergic receptor
activation induces ROS generation in numerous cell types resulting in a variety of
downstream effects including, transcription factor activation [13], pro-inflammatory
cytokine release [14, 15] and cell death [16]. Our studies determined the contribution of
ROS/RNS to extracellular ATP expression with CYP-induced cystitis and Tempol. CYPinduced cystitis increased ATP expression in the urinary bladder and cystometric fluid
that was significantly reduced by Tempol administration. It is not known from the
present studies whether antioxidant treatment directly inhibits the release of ATP through
purinergic receptor blockade. Additional studies in CYP-treated rats involving
assessment of oxidative stress in the presence of purinergic receptor (P2) blockade as
well as the effects of P2 activation on oxidative stress in controls should be considered.
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Tempol is a membrane-permeable, redox-cycling agent that scavenges
superoxide anions and decreases the formation of hydroxyl radicals [32]. The protective
effects of Tempol to tissues with inflammation and oxidative damage have been widely
established. For example, Tempol has been shown to decrease NF-kappaB activation
with acute inflammation [52], decrease neutrophil infiltration and PARP activation with
periodontitis [53], and decrease cytokine release stimulated by an inflammatory soup
[54]. In animal studies, purinergic neuromuscular transmission and propulsive motility
were significantly restored in the inflamed colon treated with the free radical scavenger,
Tempol [55]. Furthermore, intrathecal Tempol administration has been demonstrated to
decrease thermal and mechanical hypersensitivity with neuropathic pain [56]. Due to the
central and peripheral anti-inflammatory properties of Tempol, our studies determined
the role of oxidative stress on bladder function with CYP-induced cystitis and Tempol
administration. Pretreatment with Tempol and continued treatment with Tempol during
the progression of CYP-induced cystitis significantly improved urinary bladder function.
In CYP-treated (4 hr and 48 hr) rats, Tempol in the drinking water increased the
intercontraction interval and bladder capacity and reduced urinary frequency. The
presence and amplitude of NVCs during the filling phase of the urinary bladder were also
reduced in 4 hr CYP-treated rats given Tempol. Given the demonstration of Tempol
decreased mechanical hypersensitivity from neuropathic pain [56], future studies should
examine the effects of Tempol administration on somatic (i.e., pelvic, hindpaw)
sensitivity in CYP-treated rats.
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Previous studies from our laboratory have demonstrated roles for neuropeptides,
including pituitary adenylate cyclase-activating polypeptide (PACAP), CGRP and Sub P
in CYP-induced bladder dysfunction [39, 57]. Increased expression of PACAP, CGRP
and Sub P were demonstrated in the urinary bladder, lumbosacral spinal cord and dorsal
root ganglia of CYP-treated rats and pharmacological blockade of the PACAP specific
PAC1 receptor improved urinary bladder function in CYP-treated rats [39, 57]. The
present studies confirm increased expression of Sub P and CGRP in the urinary bladder
and cystometric fluid with CYP-induced cystitis (4 hr and 48 hr). Tempol treatment
significantly reduced Sub P and CGRP expression in the urinary bladder and cystometric
fluid. Previous studies demonstrated that Sub P via neurokinin (NK) receptor facilitates
bladder afferent signaling and ROS formation in bladder in association with neurogenic
inflammation [58]. Increased Sub P release increased ROS in the bladder via increased
mast cell degranulation, intercellular adhesion molecule expression, and leukocyte
adhesion. Future studies can determine the involvement of Sub P/NK receptor signaling
with these sources of ROS in the inflamed bladder following CYP-induced cystitis. The
neuropeptides, PACAP27, PACAP38 and VIP, evoked ATP release from rat urothelial
cell cultures and significantly blocked by the PAC1 receptor selective antagonist, M65
[27]. The present studies suggest two possibilities by which CYP-induced cystitis
increases ATP expression in the urinary bladder and cystometric fluid: 1) neuropeptide
(Sub P and CGRP) evoked release of ATP and 2) ROS evoked ATP release. Current
research is consistent with the suggestion that neuropeptide as well as ROS signaling are
regulators of bladder physiology at the level of the urinary bladder and possibly, the
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urothelium [27]. The present studies demonstrate that use of the antioxidant, Tempol, not
only reduces the presence of oxidative stress markers in the urinary tract but also reduces
modulators/mediators of inflammation including neuropeptides (CGRP, Sub P) also
known to contribute to micturition reflex plasticity and dysfunction with CYP-induced
cystitis. In the context of CYP-induced cystitis, Tempol treatment may be more
beneficial given its broader impact on oxidative stress markers and other modulators of
urinary bladder inflammation while also improving urinary bladder function.
The present studies demonstrate oxidative stress in the urinary tract following
CYP-induced cystitis and improvement in urinary bladder function and markers of
oxidative stress with antioxidant treatment; however, there are additional issues to be
considered. Future studies may include: 1) determining the effects of Tempol after the
induction of CYP-induced cystitis, rather than as a pretreatment, on urinary bladder
function; 2) determining if Tempol treatment can reduce somatic sensitivity in the CYP
model of urinary bladder inflammation with referred, somatic hypersensitivity; 3)
determining the effects of Tempol in a more chronic model of CYP-induced urinary
bladder inflammation that we have used extensively [23, 24]. The present studies
demonstrate that CYP-induced cystitis results in oxidative stress in the urinary tract and
that the antioxidant, Tempol, ameliorates CYP-induced bladder dysfunction. These
studies suggest that pharmacological interventions directed at oxidative stress
mediators/markers may be a promising strategy to address inflammation of the urinary
tract and target organ dysfunction.
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Figure 1: CYP-induced cystitis increases reactive oxygen species (ROS)/reactive nitrogen species
(RNS) and 3-nitrotyrosine (3-NT) in the urinary bladder and the antioxidant, Tempol, reduces
expression
A. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased ROS/RNS expression in
urothelium and detrusor that was significantly (p ≤ 0.01) reduced with Tempol. Basal expression and CYPinduced ROS/RNS expression and was significantly (p ≤ 0.01) greater in detrusor compared to urothelium.
Tempol was without effect on ROS/RNS expression in urothelium and detrusor from control (no CYP) rats.
B. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased ROS/RNS expression in urinary
bladder that was significantly (p ≤ 0.01) reduced with Tempol. Tempol was without effect on 3-NT
expression in urinary bladder from control (no CYP) rats. *, p ≤ 0.01. n=6 for control and treatment
groups.
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Figure 2: CYP-induced cystitis increases substance P (Sub P) in the urinary bladder and cystometric
fluid and the antioxidant, Tempol, reduces expression
A. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased Sub P expression in urinary
bladder that was significantly reduced with Tempol. Tempol was without effect on Sub P expression in
urinary bladder from control (no CYP) rats. B. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01)
increased Sub P expression in cystometric fluid that was significantly (p ≤ 0.01) reduced with Tempol.
Tempol was without effect on Sub P expression in cystometric fluid from control (no CYP) rats. *, p ≤
0.01. n=6 for control and treatment groups.
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Figure 3: CYP-induced cystitis increases calcitonin gene-related peptide (CGRP) in the urinary
bladder and cystometric fluid and the antioxidant, Tempol, reduces expression.
A. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased CGRP expression in urinary
bladder that was significantly (p ≤ 0.01) reduced with Tempol. Tempol was without effect on CGRP
expression in urinary bladder from control (no CYP) rats. B. 4 hr and 48 hr CYP-induced cystitis
significantly (p ≤ 0.01) increased CGRP expression in cystometric fluid that was significantly (p ≤ 0.01)
reduced with Tempol. *, p ≤ 0.01. n=6 for control and treatment groups.
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Figure 4: CYP-induced cystitis increases adenosine triphosphate (ATP) in the urinary bladder and
cystometric fluid and the antioxidant, Tempol, reduces expression
A. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01) increased ATP expression in urinary bladder
that was significantly (p ≤ 0.01) reduced with Tempol. Tempol was without effect on ATP expression in
urinary bladder from control (no CYP) rats. B. 4 hr and 48 hr CYP-induced cystitis significantly (p ≤ 0.01)
increased ATP expression in cystometric fluid that was significantly (p ≤ 0.01) reduced with Tempol.
Tempol was without effect on ATP expression in cystometric fluid from control (no CYP) rats. *, p ≤ 0.01.
n=6 for control and treatment groups.
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Figure 5: Summary histograms of the effects of Tempol (1 mM) on intercontraction interval (ICI; s),
bladder capacity (BC; µl) and void volume (VV; ml) in CYP-treated (4 hr; 48 hr) rats
Tempol in the drinking water significantly (p ≤ 0.01) increased ICI (A), VV (B) and BC (C) in CYP-treated
(4 hr and 48 hr) rats. Tempol was without effect in control (no CYP treatment) rats. *, p ≤ 0.01. Sample
sizes are n = 6 in control and treatment groups.
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Figure 6: Tempol in the drinking water was without effect on baseline pressure (A; BP), threshold
pressure (B; TP) or peak micturition pressure (C; MP; cm H20) in control or CYP-treated (4 hr; 48
hr) rats
Sample sizes are n = 6 in control and treatment groups. *, p ≤ 0.01 compared to control + vehicle (betweengroup difference).
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Figure 7: Representative cystometrogram recordings using continuous intravesical infusion of saline
in conscious rats with an open outlet from a CYP-treated (4 hr) rat with vehicle (A1-A3) and a CYPtreated (4 hr) rat with Tempol (1 mM; B1-B3)
A,B: Bladder function in a CYP-treated (4 hr) rat without Tempol (vehicle only; A1-A3) and in a CYPtreated (4 hr) rat with Tempol (1mM in the drinking water; B1-B3) during continuous intravesical infusion
of saline. Bladder function recordings in A and B are from different rats. Infused volume (IF, µl; A1, B1),
bladder pressure (BP, cm H2O; A2, B2), and void volume (VV, ml; A3, B3) with vehicle (A1-A3) and with
Tempol treatment (B1-B3) are shown. Arrows (A2, B2) indicate examples non-voiding contractions that
were significantly (p ≤ 0.01) reduced in number and amplitude in CYP-treated (4 hr) rats with Tempol.
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Figure 8: Representative cystometrogram recordings using continuous intravesical infusion of saline
in conscious rats with an open outlet from a CYP-treated (48 hr) rat with vehicle (A1-A3) and a
CYP-treated (48 hr) rat with Tempol (1 mM; B1-B3)
A,B: Bladder function in a CYP-treated (48 hr) rat without Tempol (vehicle only; A1-A3) and in a CYPtreated (48 hr) rat with Tempol (1mM in the drinking water; B1-B3) during continuous intravesical infusion
of saline. Bladder function recordings in A and B are from different rats. Infused volume (IF, µl; A1, B1),
bladder pressure (BP, cm H2O; A2, B2), and void volume (VV, ml; A3, B3) with vehicle (A1-A3) and with
Tempol treatment (B1-B3) are shown.
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